

CURRICULUM VITAE**PERSONAL INFORMATION**

Name: Lynne I. Wagner, Ph.D.

Address: Department of Social Sciences and Health Policy
Division of Public Health Sciences
Medical Center Boulevard
Winston-Salem, NC 27157

Phone: 336-713-1478

Email: lywagner@wakehealth.edu

EDUCATION

Undergraduate and Graduate Education

Doctor of Philosophy	Clinical Psychology DePaul University, Chicago IL	1997
Thesis: <i>Chronic fatigue syndrome, chronic fatigue, and psychiatric disorders: Predictors of functional status among a national nursing sample</i>		
Research Advisor: Leonard A. Jason, Ph.D.		
Master of Arts	Clinical Psychology DePaul University, Chicago, IL	1995
Bachelor of Science	Psychology University of Michigan, Flint, MI	1992

Postgraduate Training

Postdoctoral Clinical Research Fellow		1997-1999
Medical College of Wisconsin Center for AIDS Intervention Research Research Advisor: Kathleen J. Sikkema, Ph.D.		
Doctoral Internship, Clinical Psychology		1997-1999
Department of Psychiatry, The university of Chicago Hospitals Chicago, IL		

PROFESSIONAL EXPERIENCE

Professional Licensure

State of Illinois: Licensed Clinical Psychologist, 071-005890	1999-2018
---	-----------

Academic Appointments

Professor (Tenure awarded 2021) <i>Department of Social Sciences and Health Policy; Division of Public Health Sciences Wake Forest School of Medicine</i>	2015-2023
Associate Professor <i>Institute for Public Health Medicine, Northwestern University Feinberg School of Medicine</i>	2012-2015
Associate Professor <i>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine</i>	2009-2015
Associate Professor <i>Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine</i>	2008-2015
Associate Professor <i>Institute for Healthcare Studies (forerunner for newly established Institute for Public Health in Medicine), Northwestern University Feinberg School of Medicine</i>	2008-2012
Assistant Professor <i>Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine</i>	2000-2008
Assistant Professor <i>Institute for Public Health Medicine, Northwestern University Feinberg School of Medicine</i>	2000-2008
Research Assistant Professor <i>Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine</i>	1999-2000

Professional Experience

Consultant, Clinical Psychologist <i>Northwestern Medical Faculty Foundation and Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois</i>	2005-2015
Clinical Research Scientist <i>Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Chicago, Illinois</i>	2000-2009
Clinical Research Scientist <i>Rehabilitation Institute of Chicago, Rehabilitation Services Evaluation Unit, Chicago, Illinois</i>	1999-2000
Senior Research Associate <i>Cook County Bureau of Health Services, The CORE Center, Chicago, Illinois</i>	1999
Postdoctoral Research Fellow	1997-1999

*Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Sciences,
Medical College of Wisconsin, Milwaukee, WI*

Behavioral Medicine Intern	1996-1997
<i>Department of Psychiatry, The University of Chicago Hospitals, Chicago, IL</i>	
Course Instructor	1995-1996
<i>Department of Psychology, DePaul University, Chicago, IL</i>	
Research Assistant	1992-1996
<i>Department of Psychology, DePaul University, Chicago, IL</i>	

HONORS AND AWARDS

Remarkable Mentor to Women in Oncology Award Nominee	2023
<i>ECOG-ACRIN Cancer Research Group</i>	
Invited Presenter, Harry E. Hynes Memorial Lecture, Plenary Session	2015
<i>NCI Community Oncology Research Program: Accomplishments, Challenges and Opportunities Southwest Oncology Group (SWOG) Group Meeting</i>	
Plenary Session Presenter, The Commission on Cancer's Psychosocial Distress	2014
<i>Screening Quality Care Standard: How and Why It was Adopted American Psychosocial Oncology Society 11th Annual Conference</i>	
Meet-the-Expert, Distress Screening	2013-2014
<i>American Psychosocial Oncology Society 10th and 11th Annual Conferences</i>	
Recipient, National Institutes of Health (NIH) Clinical Research Loan Repayment Program	2013-2014
<i>Award, National Cancer Institute</i>	
Recipient, ECOG 2011 Young Investigator Award	2011
<i>Eastern Cooperative Oncology Group</i>	
Clinical Psychology Faculty Intern Representative	1996-1997
<i>Department of Psychiatry, University of Chicago Hospitals</i>	
Master of Arts in Clinical Psychology, awarded with Distinction	1995
<i>DePaul University, Department of Psychology</i>	

MEMBERSHIPS

Member, American Society of Clinical Oncology (ASCO) 2006-Present
I was the Chair of the ASCO Scientific Planning Committee, Health Services Research Track 2011-2012 for the ASCO 2012 Annual Meeting, and served on this committee from 2011-2015.

Member, American Psychosocial Oncology Society (APOS) 2004-Present
As noted above, I served as a Member Organization representative for APOS for two consecutive 3-year terms on the American College of Surgeons (ACoS) Commission on Cancer (CoC). During my term, I served on the ACoS Accreditation Standards Review committee. This provided me with the opportunity to successfully advance a new accreditation standard, requiring CoC-accredited cancer centers to

implement a process for the routine screening for distress among oncology patients. This standard was approved and implemented in 2015. I was invited to present my experience on the CoC and on this accomplishment during the APOS Plenary Session in 2014, to serve as an expert during Meet-the-Expert sessions at the APOS Annual Meetings 2013-2014, and to co-author a chapter in *Psycho-Oncology* (3rd Edition; Editor: J. Holland).

Member, ECOG-ACRIN Cancer Research Group (formerly Eastern Cooperative Oncology Group) 2001-Present

Since becoming a Member in 2001, I have progressively assumed greater leadership roles through the ECOG-ACRIN Cancer Research Group. I began collaborating with colleagues in ECOG-ACRIN through becoming a trial co-investigator, then assumed greater responsibility in serving as a Chair or Co-Chair for scientific committees. This led to being the recipient of the 2011 ECOG-ACRIN Young Investigator Award, being appointed as the Deputy Director of the ECOG-ACRIN Cancer Control and Outcomes Program in 2013, and Multiple-PI of the ECOG-ACRIN NCI Community Oncology Research Program (NCORP) Research Base in 2014.

Member, Society of Behavioral Medicine (SBM) 1996-Present

Member, American Psychological Association, Division of Health Psychology 1993-2015

Member, American Psychological Association (APA) 1992-2015

BIBLIOGRAPHY AND PRODUCTS OF SCHOLARSHIP

BOOKS AND BOOK CHAPTERS

1. **Wagner LI**, Pearman T. Changes in U.S. Policy: Psychosocial care as an integral component of cancer care delivery. Third edition. Oxford University Press, New York; 2015.
2. **Wagner LI**, Cella D. Psychosocial Issues in Oncology: Clinical management of psychosocial distress, health-related quality of life and special considerations in dermatologic oncology. In M. Lacouture (Ed). *Dermatologic Principles and Practice in Oncology*. Wiley, New Jersey; 2014.
3. **Wagner LI**, Cella D. Promoting symptom research in cooperative groups. In C. Cleeland, M. Fisch, & Adrian Dunn (Eds). *Cancer Symptom Science*. Cambridge, United Kingdom: Cambridge University Press; 2010:237-246.
4. Victorson D, Cella D, **Wagner L**, Kramer L, Smith M. *Measuring Quality of Life in Cancer Survivors*. In: Handbook of Cancer Survivorship (Ed. Feuerstein), Springer, New York, NY; 2007.
5. **Wagner LI**, Cella D. Quality of life and psychosocial issues. In G. Bonadonna, G. Hortobagyi, & P. Valagussa (Eds.), *Textbook of Breast Cancer: A Clinical Guide to Therapy* (3rd ed.), London, England: Taylor & Francis Group; 2006:343–362.
6. **Wagner LI**, Butt Z, Sabatino T. Prechemotherapy cognitive function in patients with cancer. *American Society of Clinical Oncology 2005 Educational Book*. 2005;392-397.

7. **Wagner LI**, Cella D, Doninger N. Cancer symptoms: Fatigue. In R. Voltz, J.L. Bernat, G.D. Borasio, I. Maddocks, D. Oliver & R. Portenoy (Eds.), *Palliative Care in Neurology*, Oxford, England: Oxford University Press; 2004:221-227.
8. **Wagner LI**, Cella D, Peterman A. Methodological considerations in the treatment of fatigue. In R. Portenoy & E. Bruera (Eds.), *Issues in Palliative Care Research in Palliative Care: Methodologies and Outcomes*, Oxford, England: Oxford University Press; 2003:173-185.
9. Aikens JE, **Wagner LI**. Diabetes mellitus and other endocrine disorders. In P.M. Camic & S.J. Knight (Eds.), *Clinical handbook of health psychology: A practical guide to effective interventions* (2nd ed.). Seattle, WA: Hogrefe & Huber; 2003.
10. Stanos SP, Harden RN, **Wagner-Raphael LI**, Saltz SL. A Prospective Clinical Model for Investigating the Development of CRPS. In R. Harden, R. Baron, & W. Janig (Eds), *Complex Regional Pain Syndrome: Progress in Pain Research and Management*, Seattle, WA: International Association for the Study of Pain Press; 2001:151-164.
11. **Wagner-Raphael L**, Cella D. Cancer-related fatigue: Clinical screening, assessment, and management. In M. Marty & S. Pecorelli (Eds.), *ESO Scientific Updates: Fatigue, Asthenia, Exhaustion and Cancer* (5th ed) Oxford, England: Elsevier Science; 2001:201-214.
12. Sikkema KJ, **Wagner LI**, Bogart LM. Gender and cultural factors in the prevention of HIV infection. In R.M. Eisler & M. Hersen (Eds.), *Handbook of gender, culture, and health*. New York: Lawrence Erlbaum Associates, Inc; 1999.
13. Aikens JE, **Wagner LI**. Diabetes and endocrine disorders. In P.M. Camic & S.J. Knight (Eds.), *Clinical handbook of health psychology: A guide to practical interventions*. Seattle, WA: Hogrefe & Huber Publishers; 1998.

Peer-Reviewed Publications

*Denotes student/mentee. **Denotes primary advisor to student/mentee

Accepted for Publication:

1. Osann, K., Wenzel L., McKinney C., **Wagner, L.**, Cella, D., Fulci, G., Scroggins, M.J., Lankes, H.A., Wang, V., Nephew, K.P., Maxwell, G.L., Mok, S.C., Conrads, T.P., Miller, A., Birrer, M. (accepted for publication). Fear of recurrence, emotional well-being and quality of life among advanced ovarian cancer survivors. *Gynecology Oncology*.
2. *Bottinor, W., Flamand, Y., Haas, N., O'Neill, A., DiPaola, R., Subramanian, P., Cella, D., Hundley, G., **Wagner, L.**, Salsman, J., Ky, B. (accepted for publication). Cardiovascular implications of vascular endothelial growth factor inhibition among adolescents/young adults in ECOG-ACRIN E2805. *Journal of the National Comprehensive Cancer Network*.

2023:

3. **Addington, E.L., Schlundt, D., Bonnet, K, Birdee G, Avis NE, **Wagner LI**, Rothman RL, Ridner S, Tooze JA, Wheeler A, Schnur JB, Sohl SJ. Qualitative similarities and distinctions between participants' experiences with a yoga intervention and an attention control. *Support Care Cancer* 31, 172 (2023).
4. Peipert, J.D., Shaunfield, S., Kaiser, K. Morena PI. Fox RS, Kircher S, Mohindra N, Ip EH, Zhao F, **Wagner LI**, Cella D. How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability? *Support Care Cancer* 31, 37 (2023).

5. Rocque GB, Andrews C, Lawhon VM, Frazier R, Ingram SA, Smith ML, **Wagner LI**, Zubkoff L, Tung N, Wallner LP, Wolff AC. Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment. *JCO Oncol Pract.* 2023 Feb;19(2):e263-e273.
6. *McLouth L, Zheng Y, Reyes SS, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini A, **Wagner LI**. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. *Qual Life Res.* 2023 Jan; 32(1): 183-196.
7. Roth ME, Parsons SK, Ganz PA, **Wagner LI**, Hinds PS, Alexander S, Bingen K, Bober SL, Brackett J, Cella D, Henry NL, Indelicato DJ, Johnson RH, Miller TP, Rosenberg SM, Schmitz KH, Thanarajasingam G, Reeve BB, Salsman JM. Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials, *JNCI: Journal of the National Cancer Institute*, Volume 115, Issue 1, January 2023, Pages 21–28.
8. **Lucas, AR, Pan, J-h, Ip, EH, Hall DH, Tooze JA, Levine B, Mohr DC, Penedo FJ, Cella D, **Wagner LI**. Validation of the Lee-Jones theoretical model of fear of cancer recurrence among breast cancer survivors using a structural equation modeling approach. *Psychooncology.* 2023; 32 (2): 256- 265.

2022:

9. Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, **Wagner LI**, Jagannath S. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect[®] MM Disease Registry. *Clinical Lymphoma Myeloma and Leukemia.* 23. 10.1016/j.clml.2022.11.008.
10. Rocque GB, Andrews C, Lawhon VM, Ingram SA, Frazier RM, Smith ML, **Wagner LI**, Zubkoff L, Wallner LP, Wolff AC. Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials, *The Oncologist*, Volume 27, Issue 12, December 2022, Pages 1067–1073.
11. Tamargo CL, Mitchell EP, **Wagner LI**, Simon MA, Carlos RC, Giantonio BJ, Schabath MB, Quinn GP. "I need more knowledge": Qualitative analysis of oncology providers' experiences with sexual and gender minority patients. *Front Oncol.* 2022; 13:763348.
12. *Hundley WG, D'Agostino RB, Crotts T, Craver K, Hackney MH, Jordan JH, Ky B, **Wagner LI**, Herrington DM, Yeboah J, Reding KW, Ladd AC, Rapp SR, Russo S, O'Connell NS, Weaver KE, Dressler EV, Ge Y, Melin SA, Gudena V, Lesser GJ. (2022). Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. *NEJM Evidence.* 1. 10.1056/EVIDoa2200097.
13. *Hall DL, Levine BJ, Jeter E, Chandler A, Tooze JA, Duffecy J, Victorson D, Gradishar W, Leach J, Saphner T, Smith ML, Penedo F, Mohr DC, Cella D, **Wagner LI**. A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention. *J Behav Med* 45, 771–781 (2022).
14. Goshe B, Rasmussen A, **Wagner LI**, Sicks J, Gareen IF, Carlos RC, Herman BA, Walter AW, Regan S, Levy D, Mahon I, Muzikansky A, Neil JM, Lui M, Dilip D, Malloy L, Gonzalez I, Fox LF, McCann C, Perez E, Ostroff J, Park E. Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]. *BMC Public Health.* 2022; 22(1): 1359.

15. Ghazal L, Cole S, Salsman J, **Wagner L**, Duan F, Gareen I, Lux L, Parsons SK, Cheung C, Loeb D, Prasad P, Dinner S, Zebrack B. Social genomics as a framework for understanding health disparities among adolescent and young adult cancer survivors: A commentary. *JCO Precision Oncology*. 2022; 6: e2100462.
16. *Fazeli S, Snyder B, Gareen IF, Lehman CD, Khan SA, Romanoff J, Gatsonis CG, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, Sparano JA, Comstock CE, **Wagner LI**, Carlos RC. Association between surgery preference and receipt in DCIS after breast MRI: Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112) Trial (E4112). *JAMA Netw Open*. 2022;5(5):e2210331.
17. **Sohl SJ, Tooze JA, Johnson EN, Ridner SH, Rothman RL, Lima CR, Ansley KC, Wheeler A, Nicklas B, Avis NE, **Wagner LI**. A Randomized Controlled Pilot Study of Yoga Skills Training Versus an Attention Control Delivered During Chemotherapy Administration. *J Pain Symptom Manage*. 2022/01/01/ 2022;63(1):23-32.
18. *Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Obeng-Gyasi S, Gareen IF, Sledge GW, Whelan TJ, Cella D, **Wagner LI**, Carlos RC. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncology*. 2022.
19. *Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O’Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, **Wagner LI**, Carlos RC. Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. *Blood Cancer J*. 2022; 12:53.
20. Khan, S., Zhao, F., Goldstein, L., Cella, D., Basik, M., Golshan, M., Julian, T., Pockaj, B, Lee, C., Razaq, W., Sparano, J., Babiera, G., Dy, I., Jain, S., Silverman, P., Fisher, C., Tevaarwerk, A., **Wagner, L**, Sledge, G. Early local therapy for the primary site in de novo Stage IV breast cancer: results of a randomized clinical trial (EA2108) *J Clinical Oncology* 2022; 40(9):978-987.
21. *Hall DL, Yeh GY, O’Cleirigh C, Peppercorn J, **Wagner LI**, Denninger J, Bullock AJ, Mizrach HR, Goshe B, Cheung T, Li R, Markowitz A, Park ER. . A Multi-step Approach to Adapting a Mind-Body Resiliency Intervention for Fear of Cancer Recurrence and Uncertainty in Survivorship (IN FOCUS). *Global Advances in Health and Medicine*. January 2022.
22. *Garcia, SF, Gray, RJ, Sparano, JA, Tevaarwerk, AJ, Carlos, RC, Yanez, B, Gareen, IF, Whelan, TJ, Sledge, GW, Cella, D, **Wagner, LI**. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. *Cancer* 2022; 536-546.
23. *Fazeli S, Snyder B, Gareen I, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, Sparano JA, Comstock CE, **Wagner LI**, Carlos RC. Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Netw Open*. 2022; 5:e2210331.
24. Carlos RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, Pisano ED, Troester MA, Timsina L, **Wagner LI**, Steingrimsson JA, Gareen I, Lee C, Adams AS, Wilkins CH. Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. *J Clin Oncol*. 2022.
25. Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flahert KT, Herman BA, Domcheck SM, DeMichele AM, Maxwell KN, Onitilo AA, Birani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Hambudiri GS,

Carlos RC, **Wagner LI**. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). *Cancer*. 2022; 128: 1381-1391.

26. Andrews C, Childers T, Wiseman K, Lawhon V, Ingram S, Smith ML, Wolff AC, **Wagner L**, Rocque GB. Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates. *BMC Cancer*. 2022; 22: 151.

2021:

27. *Yanez B, Gray R, Sparano J, Carlos RC, Sadigh G, Garcia SF, Gareen IF, Whelan TJ, Sledge GW, Cella D, **Wagner LI**. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncology*. 2021; 7: 1-7.
28. ***Wagner LI**, Tooze JA, Hall DL, Levine BJ, Beaumont J, Duffecy J, Victorson D, Gradishar W, Leach J, Saphner T, Sturtz K, Smith ML, Penedo F, Mohr DC, Cella D. Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results from the FoRtitude Randomized Trial. *J Natl Cancer Inst*. 2021;113(11):1495-1505.
29. Small W, Pugh S, **Wagner L**, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Bruner DW. Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. *International Journal of Radiation Oncology*Biophysics*Physics*. 2021; 110: 962-972.
30. *Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Sledge GW, Cella D, **Wagner LI**, Carlos RC. Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. *Cancer*. 2021;127(14):2545-2552.
31. Rocque GB, Williams CP, Andrews C, Childers TC, Wiseman KD, Gallagher K, Tung N, Balch A, Lawhon VM, Ingram SA, Brown T, Kaufmann T, Smith ML, DeMichele A, Wolff AC, **Wagner L**. Patient perspectives on chemotherapy de-escalation in breast cancer. *Cancer Medicine*. 2021;10(10):3288-3298.
32. *Obeng-Gyasi S, O'Neill A, Zhao F, Kircher SM, Lava TR, **Wagner LI**, Miller KD, Sparano JA, Sledge GW, Carlos RC. Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. *Cancer Medicine*. 2021;10(1):45-52.
33. Mayer I, Zhao F, Arteaga C, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, **Wagner LI**, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. *J CLIN ONCOL*. 2021;39: 2539-2551.
34. Lee H, Ailawadhi S, Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, **Wagner L**, Omel JL, Dhalla M, Liu L, Joshi P, Abonour R, Connect MM Registry. Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry. *Blood Cancer J*. 2021;11:134.
35. Koch V, **Wagner L**, Green H. Assessing neurocognitive symptoms in cancer patients and controls: psychometric properties of the FACT-Cog3. *Current Psychology*. 2021.
36. Kircher S, Braccio N, Gallagher K, Carlos R, **Wagner L**, Smith ML, Balch A, Benson AB. Meeting Patients Where They Are: Policy Platform for Telehealth and Cancer Care Delivery. *Journal of the National Comprehensive Cancer Network*. 2021; 19: 1470-1474.
37. *Ip E, Saldana S, Miller K, Carlos RC, Gareen IF, Sparano JA, Graham N, Zhao F, Lee JW, O'Connell NS, Cella D, Peipert JD, Gray RJ, **Wagner LI**. Tolerability of bevacizumab and chemotherapy in a phase 3

clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events. *Cancer*. 2021;127: 4546-4556.

38. *Fazeli S, Snyder B, Gareen I, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Miller KD, Sparano JA, Comstock CE, **Wagner LI**, Carlos RC. Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Netw Open*. 2021;4:e2129697.
39. Chou S-HS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberry JR, Gareen IF, Snyder BS, Gatsonis C, **Wagner LI**, Wolff AC, Miller KD, Sparano JD, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). *Radiology*. 2021;301(1):66-77.
40. *Blackstock A, Benson A, Kudo M, Jimenez H, Achari PF, McGrath C, Kirchner V, **Wagner LI**, O’Connell NS, Walker K, Pasche VK, D’Agostino R, Barbault A, Pasche B. Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma. *Open*. 2021;4:3.
41. Abonour R, Rifkin R, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Omel JL, Lee HC, Srinivasan S, Kitali A, Agarwal A, **Wagner L**, CONNECT MM Registry Investigators. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect[®] MM Registry. *British Journal of Haematology*. 2021; 193: 93-100.

2020:

42. Wong SF, Unger JM, Wade JL, **Wagner LI**, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moynour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. *J Patient Rep Outcomes*. 2020 Jul 08; 4 (1): 54.
43. **Wagner LI**, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA, Jr., Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW, Jr., Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. *J Clin Oncol*. 2020; 38 (17): 1875-1886.
44. **Wagner, LI**, Duffecy, J, Begale, M, Victorson, D, Golden, SL, Smith, ML, Penedo, FJ, Mohr, DC, & Cella, D. Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence (FoR) among breast cancer survivors. *Psycho-Oncology*. 2020; 29(1): 227–231.
45. Shi Q, Lee JW, Wang XS, Fisch MJ, Chang VT, **Wagner L**, Cleeland CS. Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. *JCO Oncol Pract*. 2020; 16 (9): e893- e901.
46. **McLouth L, Zhao F, Owonikoko T, Feliciano J, Mohindra N, Dahlberg S, Wade J, Srkalovic G, Lash B, Leach J, Leal T, Aggarwal C, Cella D, Ramalingam SS, **Wagner L**. Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN Cancer Research Group E2511 phase II randomized trial. *Cancer Medicine* 2020; 9: 7511-7523.

47. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, **Wagner LI**, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *J Clin Oncol*. 2020;38(11):1126-1137.
48. Levis B, Sun Y, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Brehaut E, Negeri Z, Fischer FH, Benedetti A, Thombs BD, Collaboration; Che L, Levis A, Riehm K, Saadat N, Azar M, Rice D, Boruff J, Kloda L, Cuijpers P, Gilbody S, Ioannidis J, McMillan D, Patten S, Shrier I, Ziegelstein R, Moore A, Akena D, Amtmann D, Arroll B, Ayalon L, Baradaran H, Beraldi A, Bernstein C, Bhana A, Bombardier C, Imma RB, Butterworth P, Carter G, Chagas M, Chan J, Chan LF, Chibanda D, Cholera R, Clover K, Conway A, Conwell Y, Daray F, de Man-van Ginkel J, Delgadillo J, Diez-Quevedo C, Fann J, Field S, Fisher J, Fung D, Garman E, Gelaye B, Gholizadeh L, Gibson L, Goodyear-Smith F, Green E, Greeno C, Hall B, Hampel P, Hantsoo L, Haroz E, Harter M, Hegerl U, Hides L, Hobfoll S, Honikman S, Hudson M, Hyphantis T, Inagaki M, Ismail K, Jeon HJ, Jetté N, Khamseh M, Kiely K, Kohler S, Kohrt B, Kwan Y, Lamers F, Lara MA, Levin-Aspenson H, Lino V, Liu S, Lotrakul M, Loureiro S, Löwe B, Luitel N, Lund C, Marrie RA, Marsh L, Marx B, McGuire A, Mohd Sidik S, Munhoz T, Kumiko Muramatsu, Juliet Nakku, Laura Navarrete, Flávia Osório, Vikram Patel, Pence B, Persoons P, Petersen I, Picardi A, Pugh S, Quinn T, Rancans E, Rathod S, Reuter K, Roch S, Rooney A, Rowe H, Santos I, Schram M, Shaaban J, Shinn E, Sidebottom A, Simning A, Spangenberg L, Stafford L, Sung S, Suzuki K, Swartz R, Tan PLL, Taylor-Rowan M, Tran T, Turner A, van der Feltz-Cornelis C, van Heyningen T, van Weert H, **Wagner L**, Wang JI, White J, Winkley K, Wynter K, Yamada M, Zeng QZ, Zhang Y. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. *JAMA*. 2020;323(22):2290-2300.
49. Levis B, Benedetti A, Ioannidis JPA, Sun Y, Negeri Z, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Rice DB, Riehm KE, Saadat N, Azar M, Boruff J, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Alamri SH, Amtmann D, Ayalon L, Baradaran HR, Beraldi A, Bernstein CN, Bhana A, Bombardier CH, Carter G, Chagas MH, Chibanda D, Clover K, Conwell Y, Diez-Quevedo C, Fann JR, Fischer FH, Gholizadeh L, Gibson LJ, Green EP, Greeno CG, Hall BJ, Haroz EE, Ismail K, Jetté N, Khamseh ME, Kwan Y, Lara MA, Liu SI, Loureiro SR, Löwe B, Marrie RA, Marsh L, McGuire A, Muramatsu K, Navarrete L, Osório FL, Petersen I, Picardi A, Pugh SL, Quinn TJ, Rooney AG, Shinn EH, Sidebottom A, Spangenberg L, Tan PLL, Taylor-Rowan M, Turner A, van Weert HC, Vöhringer PA, **Wagner LI**, White J, Winkley K, Thombs BD. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. *J Clin Epidemiol*. 2020;122:115-128.e111.
50. La L, Jagannath S, Ailawadhi S, Durie BGM, Gasparetto CJ, Hardin JW, Lee HC, Narang M, Omel JL, Rifkin RM, Terebelo HR, Toomey K, **Wagner LI**, Dhalla M, Liu L, Yang L, Joshi P, Abonour R. Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect[®] MM Registry. *Blood*. 2020;136:49-50.
51. Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, **Wagner LI**, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2020;21(10):1317-1330. doi:10.1016/S1470-2045(20)30452-6.
52. Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, **Wagner LI**, Sloan JA, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala RG, Cripps MC, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB. Intergroup randomized phase III study of postoperative oxaliplatin, 5-

fluorouracil, and leucovorin versus oxaliplatin,5-fluorouracil,leucovorin, and bevacizumab for patients with stage II or III rectal cancer receiving preoperative chemoradiation: A trial of the ECOG-ACRIN Research Group (E5204).*Oncologist* 2020; 25: e798-e807.

53. Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, **Wagner LI**, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: Results from the TAILORx trial. *JNCI* 2020; 113: 390-399.
54. Ailawadhi S, Jagannath S, Narang M, Rifkin RR, Terebelo HR, Toomey K, Durie BG, Hardin JW, Gasparetto CJ, **Wagner L**, Omel JL, Kumar V, Yue L, Kitali A, Agarwal A, Abonour R, Connect MM Registry investigators. Connect MM Registry as a national reference for United States multiple myeloma patients. *Cancer Medicine*. 2020; 9: 35-42.
55. Ailawadhi S, Jagannath S, Lee HC, Narang M, Rifkin RM, Terebelo HR, Durie BGM, Toomey K, Hardin JW, Gasparetto CJ, **Wagner L**, Omel JL, He M, Yue L, Flick ED, Agarwal A, Abonour R. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. *Cancer*. 2020; 126: 4332-4340.

2019:

56. *Upshaw JN, Ruthazer R, Miller KD, Parsons SK, Erban JK, O'Neill AM, Demissei B, Sledge G, **Wagner L**, Ky B, Kent DM. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. *Clin Breast Cancer*. 2019 Aug; 19(4):259-267.e1.
57. *Sohl SJ, Tooze JA, Wheeler A, Zeidan F, **Wagner LI**, Evans S, Kelly M, Shalowitz D, Green M, Levine B, Danhauer SC. Iterative adaptation process for eHealth Mindful Movement and Breathing to improve gynecologic cancer surgery outcomes. *Psychooncology*. 2019 Aug; 28(8):1774-1777.
58. Garcia SF, Wortman K, Cella D, **Wagner LI**, Bass M, Kircher S, Pearman T, Penedo FJ. Implementing electronic health record-integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. *Cancer*. 2019 Aug 02; 125(22): 4059–4068.
59. Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Jagannath S, **Wagner L**, Narang M, Flick ED, Srinivasan S, Yue L, Kitali A, Agarwal A, Rifkin RM. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. *British Journal of Haematology*. 2019 Aug 05; 187(5): 602–614.
60. Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, **Wagner LI**, Miller KD, Sparano JA, Comstock C. Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. *JAMA Oncol*. 2019 Jul 01; 5(7):1036-1042.
61. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, **Wagner LI**, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *N Engl J Med*. 2019 06 20; 380(25):2395-2405.

62. Obeng-Gyasi S, Kircher SM, Lipking KP, Keele BJ, Benson AB, **Wagner LI**, Carlos RC. Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape. *Cancer*. 2019 Jun 28; 125(20), 3488–3493.
63. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, **Wagner LI**, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? *Future Oncol*. 2019 May; 15(15):1683-1695.
64. Upshaw JN, O'Neill A, Carver JR, Dimond EP, Denlinger CS, Kircher SM, **Wagner LI**, Ky B, Brell JM. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. *Clin Colorectal Cancer*. 2019 03; 18(1):44-51.
65. Owonikoko TK, Dahlberg SE, Sica GL, **Wagner LI**, Wade JL, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. *J Clin Oncol*. 2019 Jan 20; 37(3):222-229.
66. Rand KL, Cohee AA, Monahan PO, **Wagner LI**, Shanahan ML, Champion VL. Coping among Breast Cancer Survivors: A Confirmatory Factor Analysis of the Brief COPE. *Journal of Nursing Measurement*. 2019;27(2):259-276.

2018:

67. Abonour R, **Wagner L**, Durie BGM, Jagannath S, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, Kitali A, Gibson CJ, Srinivasan S, Swern AS, Rifkin RM. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. *Ann Hematol*. 2018 Dec; 97(12):2425-2436.
68. *Lucas AR, Bass MB, Rothrock NE, O'Connor ML, Sorkin MR, Nawyn J, Albinali F, **Wagner LI**. Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery. *JMIR Med Inform*. 2018 Oct 22; 6(4):e46.
69. Apple AC, Schroeder MP, Ryals AJ, **Wagner LI**, Cella D, Shih PA, Reilly J, Penedo FJ, Voss JL, Wang L. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. *Neuroimage Clin*. 2018; 20:110-118.
70. Rifkin RM, Jagannath S, Durie BGM, Narang M, Terebelo HR, Gasparetto CJ, Toomey K, Hardin JW, **Wagner L**, Parikh K, Abouzaid S, Srinivasan S, Kitali A, Zafar F, Abonour R. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. *Clin Ther*. 2018 07; 40(7):1193-1202.e1.
71. Zhao F, Cella D, Manola J, DiPaola RS, **Wagner LI**, Haas NSB. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. *Support Care Cancer*. 2018 Jun; 26(6):1889-1895.
72. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, **Wagner LI**, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Moreno HG, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *New England Journal of Medicine*. 2018; 379(2):111-116.

73. Estabrook R, Cella D, Zhao F, Manola J, DiPaola RS, **Wagner LI**, Haas NB. Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: An application of the measurement model of derivatives to ECOG-ACRIN study E2805. *Quality Life Res.* 2018;27:1589-1597.
74. **Wagner LI**, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevic DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: Treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC-MA.27 (E1Z03). *Breast Cancer Res Treat.* 2018;169:537-548.
75. Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, **Wagner LI**, Gray RJ, Sparano JA, Connolly RM. E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. *NPJ Breast Cancer*, 2018;4:1.

2017:

76. Apple AC, Ryals AJ, Alpert KI, **Wagner LI**, Shih P-A, Dokucu M, Cella D, Penedo FJ, Voss JL, Wang L. Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. *NeuroImage Clin.* 2017;14:685-691.
77. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB, Jr., Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, **Wagner LI**, Foley KL, Abraham E, Pasche B, Zhang W. Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. *Theranostics.* 2017;7:2914-2923.
78. **Wagner LI**, Duffecy J, Penedo F, Mohr D, Cella D. Coping strategies tailored to the management of fear of recurrence (FoR) and adaptation for eHealth delivery: The FoRtitude trial. *Cancer.* 2017;123:906-910.
79. Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, **Wagner LI**, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: A phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx - ECOG-ACRIN Cancer Research Group. *J Clin Oncol.* 2017;35:490-497.
80. **Wagner LI**, Pugh SL, Small W, Jr., Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW. Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. *Cancer.* 2017;123:485-493.

2016:

81. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, **Wagner L**, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet.* 2016 May 14; 387(10032):2008-16.
82. Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, Bleyer WA, Freyer DR, Geiger AM, Hayes-Lattin B, Tricoli JV, **Wagner LI**, Zebrack BJ. Next Steps for Adolescent and Young Adult Oncology Workshop: An Update on Progress and Recommendations for the Future. *Cancer.* 2016;122:988-999.

83. Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB, 3rd, Rapkin BD, Weiss ES, Gareen IF, **Wagner LI**, Khan SA, Bunce MM, Small A, Weldon CB. Care for a patient with cancer as a project: Management of complex task interdependence in cancer care delivery. *J Oncol Pract*. 2016;12:1101-1113.
84. Wang L, Apple AC, Schroeder MP, Ryals AJ, Voss JL, Gitelman D, Sweet JJ, Butt ZA, Cella D, **Wagner LI**. Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors post-chemotherapy compared with healthy controls. *Cancer*. 2016;122:258-268.
85. Williams ME, Hong F, Gascoyne RD, **Wagner LI**, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. *Br J Haematol*. 2016;173:867-875.

2011-2015

86. Pearman T, Garcia S, Penedo F, Yanez B, **Wagner L**, Cella D. Implementation of distress screening in an oncology setting. *J Community Support Oncol*. 2015;13:423-428.
87. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes Geyer, Jr. CE, Dees EC, Perez EA, Olson Jr JA, Zujewski JA, Lively T, Badve SS, Saphner TJ, **Wagner LI**, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med*. 2015;373:373: 2005-2014.
88. Kaiser K, Beaumont JL, Webster K, Yount SE, **Wagner LI**, Kuzel TM, Cella D. Development and validation of the Functional Assessment of Cancer Therapy-Anti-Angiogenesis (AntiA) Subscale. *Cancer Med*. 2015;4:690-698.
89. **Wagner LI**, Schink J, Bass M, Patel S, Diaz MV, Rothrock N, Pearman T, Gershon R, Penedo FJ, Rosen S, Cella D. Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care. *Cancer*. 2015;121:927-934.
90. **Wagner LI**, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety and health-related quality of life among patients with indolent non-Hodgkin's lymphoma randomized to two different rituximab dosing regimens: Results from ECOG trial E4402 (RESORT). *J Clin Oncol*. 2015;33:740-748.
91. Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, **Wagner LI**, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C. Cancer-Related Fatigue, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Aug; 13(8):1012-39.
92. Pirl WF, Fann JR, Greer JA, Braun I, Deshields T, Fulcher C, Harvey E, Holland J, Kennedy V, Lazenby M, **Wagner L**, Underhill M, Walker DK, Zabora J, Zebrack B, Bardwell WA. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force. *Cancer*. 2014 Oct 01; 120(19):2946-54.
93. Zhao F, Chang VT, Cleeland C, Cleary JF, Mitchell EP, **Wagner LI**, Fisch MJ. Determinants of Pain Severity Changes in Ambulatory Patients with Cancer: An Analysis from Eastern Cooperative Oncology Group Trial E2Z02. *J Clin Oncol*. 2014;32:312-319.

94. Champion VL, **Wagner LI**, Monahan PO, Daggy J, Smith L, Cohee A, Ziner KW, Haase JE, Miller KD, Pradhan K, Unverzagt FW, Cella D, Ansari B, Sledge GW, Jr. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. *Cancer*. 2014;120(15):2237-2246.
95. Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, **Wagner LI**. Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. *Psychooncology*. 2014;24:523-532.
96. Jacobs DI, Kumthekar P, Stell BV, Grimm SA, Rademaker AW, Rice L, Chandler JP, Muro K, Marymont M, Helenowski IB, **Wagner LI**, Raizer JJ. Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. *Neurooncol Pract*. 2014;1:47-54.
97. Jones D, Zhao F, Fisch MJ, **Wagner LI**, Patrick-Miller LJ, Cleeland CS, Mendoza TR. The validity and utility of the M.D. Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. *Clin Genitourin Cancer*. 2014;12:41-49.
98. Kahl BS, Hong F, Williams ME, Gascoyne RD, **Wagner LI**, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab Extended Schedule or Retreatment Trial (RESORT) for Low Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. *J Clin Oncol*. 2014;32:3096-3102.
99. Lai JS, **Wagner LI**, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: Two sides of one coin? *Psychooncology*. 2014;23:1133-1141.
100. *Sanford SD, Zhao F, Salsman JM, Chang VT, **Wagner LI**, Fisch MJ. Symptom burden among young adults with breast or colorectal cancer (ECOG E2Z02). *Cancer*. 2014;120:2255-2263.
101. Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, **Wagner LI**, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ. Phase III Comparison of Tamoxifen vs. Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women with Node-Negative Hormone Receptor-Positive Breast Cancer (E3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2014;32:3948-3958.
102. Hamann HA, Lee JW, Schiller JH, Horn L, **Wagner LI**, Chang VT, Fisch MJ. Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: An analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study. *J Thorac Oncol*. 2013;8:1474-1483.
103. Kinahan K, **Wagner LI**, Pearman T, Sanford S, Didwania A. Cancer survivorship care for adult survivors of childhood cancer: An adult based model facilitating multi-disciplinary long-term follow-up care, education and research. *J Integrative Oncology*. 2013;2:1-5.
104. Mendoza TR, Zhao F, Cleeland CS, **Wagner LI**, Patrick-Miller LJ, Fisch MJ. The validity and utility of the M.D. Anderson Symptom Inventory in patients with breast cancer: Evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. *Clin Breast Cancer*. 2013;13:325-334.
105. *Sanford SD, Beaumont J, Butt Z, Sweet JJ, Cella D, **Wagner LI**. Prospective, longitudinal evaluation of a symptom cluster in breast cancer. *J Pain Symptom Manage*. 2013;47:721-730.
106. *Sanford SD, **Wagner LI**, Beaumont JL, Butt Z, Sweet JJ, Cella D. Longitudinal prospective assessment of sleep quality: Before, during and after adjuvant chemotherapy for breast cancer. *Support Care Cancer*. 2013;21:959-967.

107. Tevaarwerk AJ, Lee JW, Sesto ME, Buhr KA, Cleeland CS, Manola J, **Wagner LI**, Chang VT, Fisch MJ. Employment outcomes among survivors of common cancers: Analysis from the “Symptom Outcomes and Practice Patterns (SOAPP)” study. *J Cancer Surviv.* 2013;7:191-202.
108. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, **Wagner LI**, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence for improvement over the past three decades. *Cancer.* 2013;119:1140-1148.
109. **Wagner LI**, Spiegel D, Pearman T. Using the science of psychosocial care to implement the new ACoS Distress Screening Standard. *J Natl Compr Canc Netw.* 2013;11:214-221.
110. ***Wagner LI**, Berg SR, Gandhi M, Hlubocky FJ, Webster K, Aneja M, Cella D, Lacouture ME. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). *J Support Care Cancer.* 2013;21:1033-1041.
111. Duffecy J, Sanford S, **Wagner L**, Begale M, Nawacki E, Mohr DC. Project onward: an innovative e-health intervention for cancer survivors. *Psychooncology.* 2013 Apr; 22(4):947-51.
112. Fisch MJ, Lee JW, Weiss M, **Wagner LI**, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung or prostate cancer. *J Clin Oncol.* 2012;30:1980-1988.
113. Jacobsen PB, **Wagner LI**. A new quality standard: The integration of psychosocial care into routine cancer care. *J Clin Oncol.* 2012;30:1154-1159.
114. Joly F, Lange M, Rigal O, Correia H, Giffard B, Beaumont JL, Clisant S, **Wagner L**. French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. *Support Care Cancer.* 2012;20:3297-3305.
115. **Wagner LI**, Robinson D, Weiss M, Katz M, Greipp P, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy – Multiple Myeloma (FACT-MM): Use of qualitative and quantitative methods for scale construction. *J Pain Symptom Manage.* 2012;43:1094-1104.
116. Cella D, Wang M, **Wagner L**, Miller K. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). *Breast Cancer Res Treat.* 2011;130:855–861.
117. Loehrer PJ, Feng Y, Cardenes H, **Wagner L**, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group Trial. *J Clin Oncol.* 2011;29:4105-4112.

2005-2010

118. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, **Wagner L**, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. *Support Care Cancer.* 2010;18:509-522.
119. **Wagner LI**, Sweet JJ, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: Development of the Functional Assessment of Cancer Therapy-Cognitive Function instrument. *J Supportive Oncology.* 2009;7:W32-W39.

120. Lai JS, Butt Z, **Wagner L**, Sweet JJ, Beaumont JL, Vardy J, Jacobsen PB, Shapiro PJ, Jacobs SR, Cella D. Evaluating the dimensionality of perceived cognitive function. *J Pain Symptom Manage*. 2009;37:982-995.
121. *Butt Z, **Wagner LI**, Beaumont JL, Paice JA, Peterman AH, Shevrin D, Von Roenn JH, Carro G, Straus JL, Muir JC, Cella D. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. *J Pain Symptom Manage*. 2008;35:20-30.
122. *Butt Z, **Wagner LI**, Beaumont JL, Paice JA, Straus JL, Peterman AH, Carro G, Von Roenn JH, Shevrin D, Cella D.. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. *Support Care Cancer*. 2008;16:151-159.
123. **Wagner LI**, Beaumont JL, Ding B, Malin J, Peterman A, Calhoun E, Cella D. Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: Validation of the Functional Assessment of Cancer Therapy – Neutropenia (FACT-N). *Support Care Cancer*. 2008;16:47-56.
124. Jacobs SR, Jacobsen PB, Booth-Jones M, **Wagner LI**, Anasetti C. Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with hematopoietic stem cell transplant patients. *J Pain Symptom Manage*. 2007;33:13-33.
125. Cella D, **Wagner L**, Cashy J, Hensing T, Yount S, Lilenbaum R. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the Functional Assessment of Cancer Therapy (FACT). *J Natl Cancer Inst Monogr*. 2007;37:53-60.
126. **Wagner LI**, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II clinical trials: Lessons learned and future directions. *J Clin Oncol*. 2007;25:5058-5062.
127. Joly F, Alibhai SMH, Galica J, Park A, Yi QL, **Wagner L**, Tannock IF. Impact of androgen deprivation therapy on physical and cognitive function as well as quality of life of patients with nonmetastatic prostate cancer. *J Urol*. 2006;176:2443-2447.
128. Vardy J, Wong K, Yi QL, Park A, Maruff P, **Wagner L**, Tannock IF. Assessing cognitive function in cancer patients. *Support Care Cancer*. 2006;14:1111-1118.
129. Paterson AG, Trask PC, **Wagner LI**, Esper P, Redman B. Validation of the FACT-BRM with interferon-alpha treated melanoma patients. *Qual Life Res*. 2005;14:133-139.

1993-2004:

130. Davis K, Yount S, **Wagner L**, Cella D. Measurement and management of health-related quality of life in lung cancer. *Clin Adv Hematol Oncol*. 2004;2:533-540.
131. **Wagner LI**, Cella D. Fatigue in cancer: Causes, prevalence and treatment approaches. *British J Cancer*. 2004;91:822-828.
132. *Sweet JJ, Doninger NA, Zee PC, **Wagner LI**. Factors influencing cognitive function, sleep, and quality of life in individuals with systemic lupus erythematosus: A Review of the Literature. *Clin Neuropsychologist*. 2004;18:132-147.
133. Aikens JE, **Wagner LI**. A review of empirically based psychological assessment and intervention procedures for adults with diabetes mellitus. *Adv Med Psychotherapy*. 2002;11:59-74.
134. **Wagner-Raphael LI**, Seal DW, Ehrhardt AA. Close emotional relationships with women versus men: A qualitative study of 56 heterosexual men living in an inner-city neighborhood. *J Men's Stud*. 2001;0:243-256.

135. Pinkerton SD, **Wagner-Raphael LI**, Craun CA, Abramson PR. A quantitative study of the accuracy of college students' HIV risk estimates. *J Appl Biobehav Res.* 2000;5:1-25.
136. Seal DW, **Wagner-Raphael LI**, Ehrhardt AA. Sex, intimacy, and HIV: An ethnographic study of a Puerto Rican social group in New York City. *J Psychol Human Sexuality.* 2000;11:51-92.
137. Aikens JE, **Wagner LI**, Saelinger LJ. Reduced medical utilization and costs in anxious and depressed primary care patients receiving behavioral interventions. *Adv Med Psychotherapy Psychodiagnosis.* 1999;10:169-178.
138. **Wagner-Raphael LI**, Jason LA, Ferrari JR. Chronic fatigue syndrome, chronic fatigue, and psychiatric disorders: Predictors of functional status among a national nursing sample. *J Occup Health Psychol.* 1999;4:63-71.
139. Aikens JE, **Wagner LI**, Lickerman AJ, Chin MH, Smith A. Primary care physician responses to a panic disorder vignette: Diagnostic suspicion levels and pharmacological management strategies. *Int J Psychiatry Med.* 1998;28:179-188.
140. Jason LA, Richman JA, Friedberg F, **Wagner L**, Taylor R, Jordan KM. More on the biopsychosocial model of chronic fatigue syndrome. *Am Psychol.* 1998;53:1081-1082.
141. Jason LA. **Wagner LI**. Chronic fatigue syndrome among nurses. *Am J Nurs.* 1998;98:16B-16H.
142. Jason L, **Wagner LI**, Rosenthal S, Goodlatte J, Lipkin D, Papernik M, Plioplys S, Plioplys A. Estimating the prevalence of chronic fatigue syndrome among nurses. *Am J Med.* 1998;105:915-93S.
143. Jason LA, Richman JA, Friedberg F, **Wagner LI**, Taylor R, Jordan KM. Politics, science, and the emergence of a new disease. *Am Psychol.* 1997;52:973-983.
144. **Wagner LI**, Jason LA. Outcomes of occupational stressors on nurses: Chronic fatigue syndrome-related symptoms. *Nursing Connections.* 1997;10:41-49.
145. Jason LA, Taylor R, **Wagner L**, Holden J, Ferrari JR, Plioplys AV, Plioplys S, Lipkin D, Papernik M.. Estimating rates of chronic fatigue syndrome from a community based sample: A pilot study. *Am J Community Psychol.* 1995; 23:557-568.
146. Jason LA, **Wagner L**, Taylor R, Ropacki MT, Shlaes J, Ferrari JR, Slavich SP, Stenzel C.. Chronic fatigue syndrome: A new challenge for health care professionals. *J Community Psychol.* 1995;23:143-164.
147. Jason L, Fitzgibbon G, Taylor R, Taylor S, **Wagner L**, Johnson S, Richmond W, Papernik M, Plioplys A, Plioplys S, Lipkin D, Ferrari J. The Prevalence of Chronic Fatigue Syndrome: A Review of Efforts- Past and Present. *The CFIDS Chronicle.* 1993:24-29.
148. Jason LA, Taylor SL, Johnson S, Goldston SE, Salina D, Bishop P, **Wagner L**. Prevalence of Chronic Fatigue Syndrome-Related Symptoms among Nurses. *Evaluation & the Health Professions.* 1993;16(4):385-399.

REFEREED OTHER PRODUCTS OF SCHOLARSHIP

Presentations at Professional Meetings

*Denotes a project that included a mentee

1. *Price S, Lee J, Gareen IF, Kircher SM, Carlos RC, Kumar SK, Mayer IA, Saba NF, Fenske TS, Atkins MB, Hodi FS, Kyriakopoulos C, Tempany-Afdhal CM, Shanafelt TD, Park E, **Wagner LI**. Tobacco use, symptom burden, and symptom management perspectives among adults with cancer: baseline results from 9 ECOG-ACRIN clinical trials. Proceedings from the American Society of Prevention Oncology; March 2023.
2. Streck J, Lee J, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Kumar SK, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos C, Tempany-Afdhal CM, Shanafelt TD, **Wagner LI**, Land S, Park E, Ostroff J. Cigarette and alternative tobacco product use among adult cancer patients enrolled in 10 ECOG-ACRIN therapeutic trials. Proceedings from the Society for Research on Nicotine and Tobacco 2023; POS1-4. ABSTRACT
3. Lee HC, Abonour R, Ailawadhi S, Durie BGM, Gasparetto CJ, Hardin JW, Narang M, Omel J, Rifkin RM, Terebelo H, Toomey K, **Wagner LI**, Slaff S, Danforth D, Chung W, Anand J, Yu E, Tang D, Jagannath S. Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect[®] MM Disease Registry. *Blood* 2022; 140 (Supplement 1): 13256–13258.
4. Richter J, Ailawadhi S, Lee HC, Hardin JW, Terebelo HR, Abonour R, **Wagner LI**, Durie BGM, Omel JL, Narang M, Toomey K, Rifkin RM, Gasparetto CJ, Yu E, Anand J, Liu L, Jou YM, Jagannath S. Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect[®] MM Registry. *Blood* 2022; 140 (Supplement 1): 8089–8091.
5. Jillella AP, Lee SJ, Altman JK, Luger SM, Tallman MS, Foran JM, Law LY, Bryan LJ, Abou Zahr A, Begna KH, Perl AE, Vadakara JJ, Sanchez FA, Bergan RC, Fisch MJ, Carlos RC, **Wagner LI**, Litzow MR, Kota V. A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of ECOG-ACRIN EA9131. *Blood* 2022; 140 (Supplement 1): 1011–1013. ABSTRACT
6. Ailawadhi S, Durie BGM, Narang M, Omel J, **Wagner LI**, Toomey K, Terebelo H, Lee HC, Abonour R, Gasparetto CJ, Rifkin RM, Hardin JW, Lee K, Dhanasiri S, Gentili C, Yu E, Jou YM, Jagannath S. Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect[®] MM Registry. *Clinical Lymphoma Myeloma and Leukemia* 2022; 22. (Supplement): S161
7. Abonour R, Lee HC, Rifkin RM, Ailawadhi S, Omel J, Hardin JW, Durie BGM, Narang M, Toomey K, Gasparetto CJ, **Wagner LI**, Terebelo H, Mouro J, Dhanasiri S, Liu L, Yu E, Jagannath S. Lenalidomide, bortezomib, and dexamethasone (RVd) as first-line (1L) therapy in patients who are non-transplanted: results from the Connect[®] MM registry. *Clinical Lymphoma Myeloma and Leukemia* 2022. 22 (Supplement): S142.
8. Mao JJ, Ismaila N, Bao T, Barton D, Ben-Arye E, Garland EL, Greenlee H, Leblanc T, Lee RT, Lopez AM, Loprinzi C, Lyman GH, MacLeod J, Master AV, Ramchandran K, **Wagner LI**, Walker EM, Bruner DW, Witt CM, Bruera E. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline.. *J Clin Oncol.* 2022; 40:34, 3998-4024.
9. Frazier RM, Andrews CJ, Henderson N, Eltoum N, Thannickal HH, **Wagner LI**, Wallner LP, Wolff AC, and Rocque GB. Peeling back the curtain: The impact of patient and provider race on clinical trial enrollment.. *J Clin Oncol.* 2022; 40:28_suppl, 99-99.

10. Thannickal HH, Eltoun N, Andrews CJ, Frazier RM, **Wagner LI**, Wallner LP, Wolff AC, and Rocque GB. Academic and community physician perspectives on breast cancer biomarker use in clinical trials.. J Clin Oncol. 2022; 40:28_suppl, 349-349.
11. *Zhao F, Peipert JD, Stearns V, Chang VT, Jegede O, Ip EH, Lee J, O'Connell N, Graham N, Henry NL, Loprinzi CL, Flynn PJ, Fisch MJ, Gareen IF, Carlos RC, Smith M, Cella D, Sparano JA, Gray RJ, **Wagner LI**. Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.. J Clin Oncol. 2022; 40(16_suppl): ABSTRACT 12094
12. Walter AW, Lee J, Gareen IF, Kircher SM, Herman BA, Streck J, Kumar SK, Mayer IA, Saba NF, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos C, Tempany-Afdhal CM, Shanafelt TD, **Wagner LI**, Land S, Ostroff J, Park E. Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.. J Clin Oncol. 2022; 40(16_suppl): ABSTRACT 6514
13. Patel AA, Lee J, Zaren HA, Radeke EK, Lerner RE, Fukui JA, Makower DF, Tamkus DM, Rowland KM, Adler WM, Throckmorton AD, Ghamande SA, Hackney MH, Pippas AW, Qamar R, Cella D, Fisch MJ, **Wagner LI**. Cluster-randomized trial to evaluate the implementation of reproductive health care in cancer care delivery in community oncology practices: Results from ECOG-ACRIN E1Q11.. J Clin Oncol. 2022; 40(16_suppl). ABSTRACT 1519
14. Kircher SM, Duan F, Underwood E, Gareen IF, Sicks J, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Gokalp Yasar D, Hanson DS, Dalia SM, Acoba JD, Taylor MA, **Wagner LI**, Carlos RC. Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD.. J Clin Oncol. 2022; 40(16_suppl). ABSTRACT 6597
15. Jensen R, Zheng Y, Atkins MB, Chmielowski B, Tarhini A, Truong T, Davar D, O'Rourke MA, Curti BD, Brell JM, Kendra KL, Ikeguchi AP, Lee SJ, Potosky A, Wolchok JD, Ribas A, Kirkwood JM, **Wagner LI**, Cella D. Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).. J Clin Oncol. 2022; 40(16_suppl): ABSTRACT 9559
16. Smith K, Zhao F, Mayer I, Tevaarwerk A, Garcia S, Arteaga C, Symmans W, Park B, Burnette B, Makower D, Block M, Morley K, Jani C, Mescher C, Dewani S, Brown-Glaberman U, Flaum L, Mayer E, Sikov W, **Wagner LI**. Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. *Cancer Res.* 2022;82:P4-10.
17. Obeng-Gyasi S, O'Neill A, Miller K, Schneider BP, Partridge AH, Timsina LR, Sledge GW, **Wagner LI**, Carlos RC. Abstract PO-219: The implications of genetic ancestry and allostatic load on clinical outcomes in the ECOG-ACRIN adjuvant breast cancer trial E5103. *Cancer Epidemiol Biomarkers Prev* 2022; 31 (1_Supplement): PO-219.
18. *Peipert JD, Zhao F, Lee J, Hong F, Shen A, Ip EH, O'Connell N, Graham N, Smith M, Gareen IF, Carlos RC, Obeng-Gyasi S, Miller KD, Partridge AH, Shanafelt TD, Sparano JA, Stewart K, Tarhini A, Thomas M, Weiss M, Cella D, Gray RJ, **Wagner LI**. Change in a single-item indicator of treatment tolerability in cancer is associated with early treatment discontinuation. *Qual Life Res.* 2021; 30(1). ABSTRACT 115.3
19. **Wagner L**, Abonour R, Ailawadhi S, Durie BGM, Gasparetto CJ, Hardin JW, Lee H, Narang M, Rifkin R, Terebelow H, Toomey K, Joshi P, Agarwal A, Braverman J, Dhanda DS, He M, Jagannath S. P-136: Health-related quality of life (HRQL) among real-world Ide-Cel-eligible patients (pts) with relapsed/refractory

- Multiple Myeloma (RRMM): results from the Connect® MM registry. *Clinical Lymphoma Myeloma and Leukemia*. 2021;21:S109.
20. Trosman J, Sicks J, Weldon C, Tsongalis GJ, Rapkin B, Weaver KE, Cohen GI, Lad TE, Dressler EVM, Stanfield B, Hopkins JO, Hancock J, Kehn H, Steen PD, **Wagner LI**, Carlos R. Biomarker testing in non-small cell lung cancer (NSCLC): An assessment of current practices in precision oncology in the community setting—A trial of the ECOG-ACRIN cancer research group (EAQ161CD). *J CLIN ONCOL*. 2021;39:e18649-e18649.
 21. Tang D, Hari P, Ramasamy K, Weisel K, Joshi P, Liu L, Che M, Hernandez G, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Lee HC, Terebelo HR, Durie BGM, Narang M, Toomey K, Gasparetto C, **Wagner LI**, Jagannath S. Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry. *Blood* 2021;138:117-117.
 22. Stearns V, Jegede O, Chang VT, Skaar TC, Berenberg JL, Nand R, Lyss AP, Jacobs NL, Luginbuhl WE, Gilman P, Benson A, Goodman JR, Buchschacher GL, Henry NL, Loprinzi CL, Flynn PJ, Mitchell EP, Fisch MJ, Sparano JA, **Wagner LI**. Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. *J CLIN ONCOL* 2021;39:12003-12003.
 23. Smith M, Jegede O, Martin P, Till BG, Parekh SS, Yang DT, Kostakoglu L, Casulo C, Bartlett NL, Caimi PF, Baghdadi TA, Maddocks KJ, Romer MD, Inwards DJ, Lerner RE, **Wagner LI**, Little RJ, Friedberg JW, Leonard JP, Kahl BS. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. *J CLIN ONCOL* 2021;39:7503-7503.
 24. Pophali P, Wang X, Zhao F, Kay NE, Hanson CA, Thomas ML, O'Brien SM, Barrientos J, Paietta EM, Leis JF, Zhang CC, Coutre S, Barr PM, Cashen A, Mato AR, Singh A, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Shanafelt T, **Wagner LI**. Quality of Life in Patients ≤70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912. *Blood* 2021;138:1562-1562.
 25. Obeng-Gyasi S, O'Neill A, Miller K, Schneider BP, Partridge AH, Timsina LR, Sledge GW, **Wagner LI**, Carlos R. Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103. *J Clin Oncol* 2021; 39:6527-6527.
 26. *Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Cella D, Zhao F, Ip E, O'Connell N, Hong F, Peipert JD, Gareen IF, Gray RJ, **Wagner LI**, Carlos R. Association between allostatic load, symptom burden and mortality in E1A11 trial for myeloma. *J CLIN ONCOL* 2021;39:12102-12102.
 27. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Mayer EL, Sikov WM, Rodler ET, **Wagner LI**, DeMichele AM, Sparano JA, Wolff AC, Miller KD. A randomized phase III post-operative trial of platinum-based chemotherapy (P) vs. capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131. *J Clin Oncol*. 2021; 39(15). ABSTRACT 605
 28. Kumar S, Wei Z, Thompson MA, Snyder B, Weiss M, **Wagner LI**, Kostakoglu L, Rajkumar SV. ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation. *J CLIN ONCOL* 2021;39:TPS8052-TPS8052.

29. Kircher S, Duan F, Gareen I, Underwood E, Sicks J, Suga JMM, Kehn H, Mehan PT, Acoba JD, Taylor MA, **Wagner LI**, Carlos R. Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: Early results of ECOG-ACRIN EAQ162CD. *J CLIN ONCOL* 2021;39:1518-1518.
30. Fazeli S, Snyder BS, Gareen IF, Lehman CD, Khan SA, Romanoff J, Gatsonis C, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, Sparano JA, Comstock C, **Wagner LI**, Carlos RC. Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112). *J Clin Oncol*. 2021; 39(15): ABSTRACT 6564
31. Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia JJ, Ringash J, Lewin JS, Duvvuri U, O'Malley BW, Orzer E, Thomas GR, Koch W, Kupferman ME, Bell RB, Saba NF, Lango M, **Wagner LI**, Burtness B. Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). *J CLIN ONCOL*. 2021;39:6010-6010.
32. *Peipert JD, Zhao F, Lee J, Hong F, Ip EH, Gareen IF, O'Connell NS, Carlos RC, Stewart K, Weiss M, Sparano JA, Cella D, Gray RJ, **Wagner LI**. Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients. *J Clin Oncol*. 2020; 38(Suppl): ABSTRACT e19136
33. Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia S, Gareen IF, Whelan TJ, Sledge GW, Cella D, **Wagner LI**. Early discontinuation to adjuvant endocrine therapy in the TAILORx trial. Oral Abstract Session, Health Services Research and Quality Improvement 2020 Annual Meeting of the American Society of Clinical Oncology.
34. Peipert JD, Zhao F, Lee J, Hong F, Ip EH, Gareen IF, Carlos RC, Mayer IA, Miller KD, Partridge AH, Shanafelt TD, Stewart K, Tarhini A, Thomas M, Weiss M, Cella D, Gray RJ, **Wagner LI**. Analysis of ECOG-ACRIN clinical trials to advance longitudinal assessment of cancer treatment tolerability. *Qual Life Res*. 2020; 29(S1): S13. ABSTRACT
35. Khan SA, Zhao F, Solin LJ, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Razaq W, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, **Wagner LI**, Sledge GW. A randomized Phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). 2020 Annual Meeting of the American Society of Clinical Oncology.
36. Bradbury AR, Lee J, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, **Wagner LI**. Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial. Oral abstract session, Care Delivery and Regulatory Policy. 2020 Annual Meeting of the American Society of Clinical Oncology.
37. Peipert JD, Zhao F, Lee J, Hong F, Ip E, Gareen IF, Carlos RC, Mayer IA, Miller KD, Partridge AH, Shanafelt TD, Stewart K, Tarhini A, Thomas M, Weiss M, Cella D, Gray RJ, **Wagner LI**. EVOLV: Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms. Presentation at the International Society for Quality of Life Research (ISOQOL) 27th Annual Conference. *Qual Life Res* 29 (Suppl 1), 13 (2020).
38. *Zhao F, Peipert JD, Lee J, Hong F, Ip E, Gareen IF, O'Connell N, Carlos RC, Mayer IA, Miller KD, Partridge AH, Shanafelt TD, Stewart K, Tarhini A, Thomas M, Weiss M, Sparano JA, Cella D, Gray RJ, **Wagner LI**. Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment

- discontinuation in clinical trials. Online publication, 2020 Annual Meeting of the American Society of Clinical Oncology.
39. Tarhini A, Zheng Y, Lee SJ, Hodi FS, Rao UN, Cohen GI, Sondak VK, Kirkwood JM, **Wagner LI**. Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life analysis of ECOG-ACRIN E1609. 2020 Annual Meeting of the American Society of Clinical Oncology.
 40. Tamargo C, Mitchell EP, **Wagner LI**, Simon MA, Carlos RC, Giantonio BJ, Quinn GP, Schabath MB. Abstract PO-013: Qualitative results to a survey of ECOG-ACRIN members regarding experience with sexual and gender minority patients with cancer. Oral presentation AACR Virtual Conference: Thirteenth AACR conference on the science of cancer health disparities in racial/ethnic minorities and the Medically Underserved. *Cancer Epidemiol Biomarkers Prev* 2020; 29 (12_Supplement): PO-013.
 41. Schabath M, Perez-Morales J, Sutter M, **Wagner L**, Simon M, Carlos RC, Giantonio BJ, Quinn GP, Mitchell EP. Survey of healthcare providers in the ECOG-ACRIN cancer research group: Attitudes, knowledge, and practice behaviors about LGBTQ patients with cancer. Oral presentation AACR Virtual Conference: Thirteenth AACR conference on the science of cancer health disparities in racial/ethnic minorities and the Medically Underserved. *Cancer Epidemiol Biomarkers Prev* 2020; 29 (12_Supplement): PO-068.
 42. Sadigh G, Gray RJ, Yanez B, **Wagner LI**, Garcia S, Sparano JA, Cella D, Carlos RC. Breast cancer patients' insurance status correlates with their adherence to endocrine therapy: Analysis of TAILORx trial. Presentation in the Poster Session, Health Services Research and Quality Improvement. 2020 Annual Meeting American Society of Clinical Oncology.
 43. Perez G, Hong F, Evens A, Habermann TM, Advani R, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JW, Chang JE, Cella D, Kahl BS, **Wagner LI**. Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Poster presentation American Society of Hematology 2020 Annual Meeting. *Blood*. 2020;136:45-46.
 44. Obeng-Gyasi S, O'Neill A, Zhao F, Kircher SM, Timisina LR, **Wagner LI**, Miller KD, Sparano JA, Sledge GW, Carlos RC. Impact of insurance and socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. *Cancer Res*. 2020; 80(45). ABSTRACT PD10-09
 45. Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, **Wagner LI**, Rajkumar SV. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Plenary presentation, ASCO 2020 Annual Meeting. *J CLIN ONCOL*. 2020;38:LBA3-LBA3.
 46. Khan S, Zhao F, Solin L, Goldstein LJ, Cella D, Basik M, Golshan M, Julian RB, Pockaj BA, Lee CA, Wajeeha R, Sparano JA, Babiera GB, Dy IA, Jain S, Silverman P, Fisher C, Tevaarwerk AJ, **Wagner LI**, Sledge GW. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Plenary presentation, ASCO 2020 Annual Meeting. *J CLIN ONCOL*. 2020;38:LBA2-LBA2.
 47. Dent S, Reding K, Lesser G, Klepin HD, **Wagner LI**, Kitzman D, Brubaker PH, Mihalko S, Avis NE, Winkfield KM, Ky B, Crotts T, Kikuchi R, Calhoun, Hundley WG. Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center Wake Forest NCORP research-base study. *J CLIN ONCOL*. 2020; 38:TPS602-TPS602.

48. Ailawadhi S, Lee H, Omel J, Toomey K, Hardin JW, Gasparetto C, Jagannath S, Rifkin RM, Durie BG, Narang M, Terebelo HR, **Wagner LI**, Dhalla M, He M, Srinivasan S, Joshi PR, Robinson S, Abonour R. Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry. *J CLIN ONCOL*. 2020; 38:8518-8518.
49. Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, **Wagner LI**, Mihalciou C, Desbiens C, Hayes DF, Dees EC, Geyer CE, Olson JA, Wood WC, Lively T, Paik S, Ellis MC, Abrams JS, Sledge GW. Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx. *Ann Oncol*. 2019; 30(5s). ABSTRACT v851-v934
50. Radeke EK, Lee J, Patel AA, Zaren HA, Fisch MJ, **Wagner LI**. Reproductive health in cancer. *J Clin Oncol*. 2019; 37(Suppl). ABSTRACT TPS6649
51. Lonial S, Jacobus S, Weiss M, Kumar SK, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien TE, Matous JV, Anderson DM, Emmons RV, Dhodapkar MV, **Wagner LI**, Rajkumar SV. E3A06: Randomized phase III trial OF lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. *J Clin Oncol*. 2019; 37(Suppl): ABSTRACT 8001
52. **Wagner LI**, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos RC, Gareen IF, McCaskill-Stevens W, Cella D, Sparano JA, Sledge GW. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. *Cancer Res*. 2019; 79(4S): ABSTRACT GS6-03
53. Albain KS, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, **Wagner LI**, Whelan TJ, Ellis MC, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams JS, Sledge GW. Race, ethnicity, and clinical outcomes in hormone-receptor-positive, HER2-negative, node-negative breast cancer: Results from the TAILORx trial. *Cancer Res*. 2019; 79(4S). ABSTRACT GS4-07
54. **Wagner L**, Toomey K, Ailawadhi S, et al. Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect[®] MM Registry. Poster presentation at the 2019 American Society of Hematology Annual Meeting. *Blood*. 2019;134:1843-1843.
55. Morgan AK, Chen Y, Jarrard DF, Carducci MA, DiPaola RS, **Wagner LI**, Cella D, Sweeney CJ. Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. *Ann Oncol*. 2018; 29(8): ABSTRACT 832P
56. Shi Q, Lee J, Wang XS, Fisch MJ, Manola J, **Wagner LI**, Chang VT, Cleeland C. Patient-reported symptom interference as a potential measure for tolerability of cancer treatment: Evidence from ECOG-ACRIN SOAPP. Proceedings from the International Society for Quality of Life Research. 2018; 27(S1): ABSTRACT 1127
57. Upshaw JN, Ruthazer R, Miller KD, Parsons SK, Erban JK, O'Neill A, **Wagner LI**, Ky B, Kent DM. A tool for personalized decision making: A clinical prediction model for anthracycline toxicity in early stage breast cancer. *J Amer Coll Cardio*. 2018; 71(11S): A696. ABSTRACT 13
58. **Wagner L.I.**, Canzona, M., Tooze, J.A., Weaver, K.E., Shore, K., Peters, L., Petty, W.J., Porosnicu, M., Zhang, W., & Pasche, B. (2018). Mixed methods examination of diverse patients' experiences with precision oncology. *J Clin Oncol*. 36 (15_suppl):e22148-e22148. Published abstract.

59. **Wagner LI**, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, on behalf of the TAILORx Study Team. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. Oral presentation, San Antonio Breast Cancer Symposium, December 7, 2018.
60. Tevaarwerk A, Lee JW, **Wagner LI**, et al. Factors associated with loss of employment among metastatic patients. *Poster presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 32, 5S: Abstract 6585; 2014.*
61. Ghia P, O'Brien SM, **Wagner LI**, et al. Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients with relapsed chronic lymphocytic leukemia (CLL): Phase III results. *Poster presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 32, 5S: Abstract 7099; 2014.*
62. Cmelak A, Li S, **Wagner LI**, et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). *Oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 32, 5S: Abstract LBA6006; 2014*
63. **Wagner LI**, King K, Kozlowski C, et al. Integrating a web-based assessment to identify distress into routine cancer care: Clinical application of the PROMIS computer adaptive test. *Oral presentation at the American Psychosocial Oncology Society 10th Annual Conference; 2013.*
64. **Wagner LI**, Abraham LA, King K, et al. Integrating the Patient-Reported Outcomes Measurement Information System symptom assessment into routine cancer care. *Poster presentation at the 32nd Annual North American Meeting of the Society for Medical Decision Making; 2012.*
65. Zhao F, **Wagner LI**, Pirl WF, Miller AH, Fisch M. Racial disparities in depressive symptom prevalence and selective serotonin reuptake inhibitor (SSRI) utilization in cancer patients: An analysis from ECOG E2202: Symptom Outcomes and Practice Patterns (SOAPP). *Poster presentation at the 48th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 30, Abstract 6076; 2012.*
66. Williams ME, Hong F, **Wagner LI**, et al. A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. *Oral presentation at the 48th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 30, Abstract 8007; 2012.*
67. **Wagner LI**, Gray R, Sledge G, et al. Patient-reported cognitive impairments among women with breast cancer randomized to hormonal therapy alone versus chemotherapy followed by hormonal therapy: Results from the TAILORx trial (PACCT-1). *Poster presented at the International Cognition and Cancer Task Force Conference; 2012*
68. **Wagner LI**, Gray R, Sledge G, et al. Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx). *Poster presentation at the 48th Annual Meeting of the American Society of Clinical Oncology Journal of Clinical Oncology. 2012;30S:9020.*
69. **Wagner LI**. Health Services Research Poster Discussant: Quality of Cancer Survivorship Care. *Oral presentation at the 48th Annual Meeting of the American Society of Clinical Oncology; 2012.*

70. Lai JS, Krull KR, Zelko F, **Wagner LI**, Cella D, Goldman S. Parent-reported cognition and its clinical applications in pediatric oncology. *Poster presentation at the 48th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 30, Abstract 9532; 2012.*
71. Arteaga CL, Mayer IA, **Wagner LI**, et al. A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). *Poster presentation at the 48th Annual Meeting of the American Society of Clinical Oncology. Abstract: Journal of Clinical Oncology 30, Abstract 605; 2012.*
72. Kahl BS, Hong F, **Wagner LI**, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. *Oral presentation at the 53rd Annual Meeting of the American Society of Hematology; 2011.*
73. Fisch M, Lee J, **Wagner LI**, et al. Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. *Oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology. Abstract: J Clin Oncol. 2011;29:6008S.*
74. Chang VT, Zhao F, **Wagner LI**, Sanford SD, Salsman J, Fisch M. Symptom burden and change among adolescent/young adult (AYA) patients with breast, lung, colorectal, or prostate cancer. *Poster presentation at the 47th Annual Meeting of the American Society of Clinical Oncology. Abstract: J Clin Oncol. 2011;29:9064S.*
75. **Wagner LI**, Zhao F, Chapman JA, et al. Patient-reported predictors of treatment discontinuation: NCIC JMA.27/E1Z03 Quality of life among postmenopausal women with primary breast cancer randomized to exemestane or anastrozole. *Oral presentation at the 34th Annual San Antonio Breast Cancer Symposium. Abstract: Cancer Research. 2011;71:(24)S6.*
76. Weiss M, Jacobus S, **Wagner LI**, et al. Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) scale and validation: Eastern Cooperative Oncology Group Trial E1A05. *Poster presentation at the 53rd Annual Meeting of the American Society of Hematology; 2011.*
77. **Wagner LI**, Zickl L, Smith ML, et al. Prospective assessment of symptom burden among cancer survivors with common solid tumors: Results from ECOG trial E2Z02. *Poster presentation at the 47th Annual Meeting of the American Society of Clinical Oncology. Abstract: J Clin Oncol. 2011;29:9137S.*
78. **Wagner LI**, Duffecy J, Lehman KA, et al. Randomized clinical trial to evaluate an e-health intervention for fear of cancer recurrence, anxiety and depression among cancer survivors. *Trials in Progress Poster presentation at the 47th Annual Meeting of the American Society of Clinical Oncology; 2011.*
79. **Wagner LI**, Zaluda L, Guitart J, Kuzel T, Querfeld C, Rosen S. Health-related quality of life among patients with cutaneous lymphoma (CTCL): Development of the Functional Assessment of Cancer Therapy (FACT) – CTCL. *Oral presentation at the First World Congress of Cutaneous Lymphomas. Chicago, IL; 2010.*
80. **Wagner LI**, Rosenbaum SE, Gandhi M, et al. Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFRI. *Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: J Clin Oncol. 2010;28:15S.*
81. **Wagner LI**. Cancer and cognitive impairment: Measuring cognitive function. Padgett, L., Wagner, L.I. & Ferguson, R. Cancer and cognitive impairment: Management of cognitive impairment in adults with cancer. *Workshop held at the American Psychosocial Oncology Society 7th Annual Conference; 2010.*

82. Tevaarwerk A, Lee J, **Wagner LI**, et al. Predictors of employment outcomes in outpatients with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study). Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2010;28:15S.
83. *Sanford SD, **Wagner LI**, Beaumont JL, Butt Z, Sweet JJ, Cella D. Longitudinal prospective assessment of sleep disturbance in breast cancer. Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2010;28:15S.
84. Jacobs D, Grimm SA, **Wagner LI**, et al. Quality-of-life concordance between patients with malignant gliomas (MG) and their caregivers. Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2010;28:15S.
85. Jacobs D, Grimm SA, **Wagner LI**, et al. Assessing the financial burden experienced by insured malignant glioma patients. Abstract: *Neuro-Oncology*. 2010;12:(S4)iv102.
86. Hamann HA, Lee J, **Wagner LI**, et al. Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02). Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2010;28:15S.
87. Fisch M, Lee J, **Wagner LI**, et al. A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study). Poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2010;28:15S.
88. Chang V, Lee JW, **Wagner L**, Weiss M, Cleeland C, Fisch M. A prospective evaluation of functional change over 4 weeks for outpatients with common solid tumors: Results from ECOG E2Z02 (The SOAPP study). Poster presented at the annual meeting of the Multi-National Association for Supportive Care in Cancer (MASCC). Abstract: *Support Care Cancer*. 2010;18:(Suppl 3)S159.
89. Fisch M, Lee JW, **Wagner L**, et al. Survey of disease and treatment-related symptoms in outpatients with invasive cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study). Poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2009;27:15S.
90. Cardenes HR, Powell M, **Wagner LI**, et al. E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis. Poster presented at the 45th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2009;27:15S.
91. Witherspoon JN, **Wagner L**, Rademaker A, West D, Rosenbaum S, Lacouture ME. Correlation of patient factors and NCI-Common Terminology criteria for adverse events (CTCAE) v 3.0 grading with dermatology-related quality of life (QOL) in patients with EGFR inhibitor induced rash. Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2008;26S.
92. Vardy J, Xu W, **Wagner L**, et al. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. Oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2008;26S.
93. Loehrer PJ, Powell M, **Wagner L**, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology. Abstract: *J Clin Oncol*. 2008;26S.

94. *Garcia S, **Wagner L**, Choi SW, George J, Cella D. Patient-Reported Outcomes Measurement Information System (PROMIS) Cancer-Specific Perceived Cognitive Function Item Banks. Poster presented at the 15th Annual Conference of the International Society for *Quality of Life Research*. 2008;17.
95. **Wagner LI**. Measuring patient reported outcomes in cancer clinical trials: Considerations in the assessment of older adults. *Symposium presented at the 28th Annual Meeting and Scientific Sessions of the Society of Behavioral Medicine*; 2007.
96. **Wagner L**, Lai SE, Aneja M, et al. Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. *Abstract: J Clin Oncol*. 2007;25:18S.
97. **Wagner LI**, Sweet JJ, Butt Z, et al. Trajectory of cognitive impairment during breast cancer treatment: A prospective analysis. Paper presented at a Clinical Science Symposium at the 42nd Annual Meeting of the American Society of Clinical Oncology. *Abstract: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1*. 2006;24:18S.
98. **Wagner L**, Wang M, Miller K, et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: Results from the Eastern Cooperative Oncology Group (ECOG) Study E2100. Poster presented at the 29th Annual San Antonio Breast Cancer Symposium. *Abstract: Breast Cancer Research and Treatment*. 2006;100:(S1)S239.
99. Desai J, **Wagner LI**, Beaumont JL, Sweet JJ, Butt Z, Cella D. Cognitive functioning among breast cancer patients prior to chemotherapy. *Abstract: Psycho-oncology*. 2005;14:(1S)S32.
100. **Wagner LI**, Sweet JJ, Desai J, et al. Pre-chemotherapy hemoglobin (Hgb) and cognitive impairment among breast cancer patients. Poster presented at the 41st Annual Meeting of the American Society of Clinical Oncology. *Abstract: Proceedings of the American Society of Clinical Oncology*. 2005;23:(16S)760S.
101. Jacobs SR, Jacobsen PB, Booth-Jones M, **Wagner LI**. Psychometric Properties and Correlates of the FACT-Cog, A Recently Developed Self-Report Measure of Cognitive Complaints for Use with Cancer Patients. Poster presented at the 1st Annual Meeting of the American Psychosocial Oncology Society, Orlando, Florida. *Abstract: Psycho-Oncology*. 2004;13:(S1)S31.
102. **Wagner LI**, Lai JS, Cella D, Sweet J, Forrestal S. Chemotherapy-related cognitive deficits: Development of the FACT-Cog instrument. Poster presented at the 25th Annual Scientific Session of the Society of Behavioral Medicine, Baltimore, Maryland. *Abstract: Annals of Behavioral Medicine*. 2004;27:S10.
103. **Wagner LI**, Sweet JJ, Cella D, et al. Performance of cognitively impaired oncology patients and normal controls on functional MRI tasks. Poster presented at the 30th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. *Abstract: Proceedings of the American Society of Clinical Oncology*. 2004;23:731.
104. Jacobsen PB, **Wagner LI**, Kissane D, Holland JC. Recognizing and Treating Distress in Ambulatory Patients: Rapid Screening and Impact on Quality of Life of Patients. *Special session presented at the 30th Annual Meeting of the American Society of Clinical Oncology*, New Orleans, LA; 2004.
105. **Wagner LI**, Rosenbloom S, Purpura-Kilroy L, et al. Utilizing technology to deliver a patient and provider intervention for the management of cancer-related fatigue, pain, anxiety and depression: Development of a web-based symptom management program. *Poster presented at the 7th Annual World Congress of Psycho-Oncology*, Copenhagen, Denmark; 2004.

106. **Wagner LI**, Eremenco S, Herzberg T, Du H, Schuett G, Lai JS. FACT-Cog for use in German clinical oncology trials: Linguistic validation and the examination of psychometric properties of the FACT-Cob German translation. *Poster presented at the 7th Annual World Congress of Psycho-Oncology*, Copenhagen, Denmark; 2004.
107. Lai JS, Rosenbloom S, Cella D, **Wagner L**, Item banking co-investigators. Building core HRQL measures: Positive and negative psychological impact of cancer. *Paper presented at the 11th Annual Conference of the International Society for Quality of Life Research*, Hong Kong, China; 2004.
108. **Wagner LI**, Sweet J, Cella D, Doninger N. Chemotherapy-related cognitive deficits: A qualitative examination of providers and patients. Poster presented at the 24th Annual Scientific Session of the Society of Behavioral Medicine, Salt Lake City, Utah. Abstract: *Annals of Behavioral Medicine*. 2003;25:S56.
109. **Wagner LI**, Cella D, Cashy J, et al. Single item screening to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory oncology practice. Poster presented at the 29th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois. Abstract: *Proceedings of the American Society of Clinical Oncology*. 2003;22:527.
110. **Wagner LI**, Rue M, Fisch M, et al. Neuropsychiatric symptoms during cancer treatment: An examination of quality of life data from two ECOG lung cancer trials. Paper presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida. Abstract: *Proceedings of the American Society of Clinical Oncology*. 2002;21:357a.
111. **Wagner-Raphael LI**, Peterman AH, Cella D. Cancer-related fatigue: Longitudinal relationship to mood and sleep disturbance. Paper presented at the 22nd Annual Scientific Session of the Society of Behavioral Medicine, Seattle, Washington. Abstract: *Annals of Behavioral Medicine*. 2001;23:S201.
112. Hunter P, **Wagner-Raphael LI**. Sex, drugs, and preventing HIV infection. *Seminar presented at the 30th Annual Winter Refresher Course for Family Physicians*, Waukesha, Wisconsin; 2000.
113. Stanos SP, Hankley DW, **Wagner-Raphael L**, et al. Signs and symptoms of Complex Regional Pain Syndrome (CRPS) following total knee arthroplasty: A prospective study. *Poster presented at the Annual Meeting of the American Association of Academic Psychiatrists*, La Jolla, California; 2000.
114. **Wagner-Raphael LI**, Bruehl S, Harden RN, Heinemann AW. Age-related differences in adjustment to chronic pain. Poster presented at the 21st Annual Scientific Session of the Society of Behavioral Medicine, Nashville, Tennessee. Abstract: *Annals of Behavioral Medicine*. 2000;22:S200.
115. **Wagner-Raphael LI**. Primary care physician-delivered HIV prevention: A pilot intervention. Paper presented at the 21st Annual Scientific Session of the Society of Behavioral Medicine, Nashville, Tennessee. Abstract: *Annals of Behavioral Medicine*. 2000;22:S39.
116. **Wagner-Raphael LI**, Keane T, Winiarski MG, Acuff C. Models for delivering integrated HIV/AIDS treatment: A multi-site study. Symposia presented at the 21st Annual Scientific Session of the Society of Behavioral Medicine, Nashville, Tennessee. Abstract: *Annals of Behavioral Medicine*. 2000;22:S32.
117. **Wagner-Raphael LI**. Primary care-based HIV/AIDS prevention: Providers' attitudes and practices. Paper presented at the 20th Annual Scientific Session of the Society of Behavioral Medicine, San Diego, California. Abstract: *Annals of Behavioral Medicine*. 1999;21:S116.
118. **Wagner LI**, Sikkema KJ, Bogart LM. Distress, physical symptoms, and coping among people with HIV. Poster presented at the 19th Annual Scientific Session of the Society of Behavioral Medicine, New Orleans, Louisiana. Abstract: *Annals of Behavioral Medicine*. 1998;20:S153.

119. **Wagner LI**, Cecil H, Pinkerton SD. HIV prevention and the Health Belief Model: Perceptions of the female condom among a clinic-based Latino population. Paper presented at the 19th Annual Scientific Session of the Society of Behavioral Medicine, New Orleans, Louisiana. Abstract: *Annals of Behavioral Medicine*; 1998;20:S49.
120. **Wagner LI**. Family practitioner-based HIV/AIDS prevention. *Poster presented at the 7th Annual Research Forum at the Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin*; 1998.
121. **Wagner LI**, Bogart LM. HIV prevention and Hispanic women: Predicting female condom use intentions. *Poster presented at the 106th Annual Convention of the American Psychological Association, San Francisco, California*; 1998.
122. Aikens JE, **Wagner LI**, Setzer NS, Smith A. Panic disorder recognition and management by primary care physicians. Poster presented at the 18th Annual Scientific Session of the Society of Behavioral Medicine. Abstract: *Annals of Behavioral Medicine*. 1997;19:S172.
123. Aikens JE, **Wagner LI**, Setzer NJ, Saelinger LJ. Cost effectiveness of behavioral medicine: Long term decreases in medical utilization and costs. Poster presented at the 18th Annual Scientific Session of the Society of Behavioral Medicine. Abstract: *Annals of Behavioral Medicine*. 1997;19:S86.
124. Jason LA, Jordan KM, **Wagner LI**, et al. Multidisciplinary training as an educational experience for awareness of emerging health disorders. *Symposium presented at the 104th Annual Convention of the American Psychological Association, Toronto, Ontario, Canada*; 1996.
125. Jason LA, Jordan KM, **Wagner LI**, et al. Epidemiological perspective on the new case definition of chronic fatigue syndrome. *Symposium presented at the 104th Annual Convention of the American Psychological Association, Toronto, Ontario, Canada*; 1996.
126. **Wagner LI**, Jason LA. Occupational stressors and chronic fatigue syndrome symptoms: An examination of nurses. *Paper presented at the 67th annual meeting of the Midwestern Psychological Association, Chicago, IL*; 1995.
127. Haney-Davis T, Banghart MA, **Wagner LI**, et al. Community building: Developing new supports for disenfranchised populations. *Panel presented at the 67th annual meeting of the Midwestern Psychological Association, Chicago, IL*; 1995.
128. **Wagner LI**, Jason LA. Occupational stressors and chronic fatigue syndrome symptoms: An examination of nurses. *Poster presented at the biennial conference for the Society for Community Research and Action, Chicago, IL*; 1995.
129. Jason LA, **Wagner L**, Holden JG. Chronic fatigue syndrome: Epidemiological approaches to estimating prevalence rates. *Poster presented at the 66th annual meeting of the Midwestern Psychological Association, Chicago, IL*; 1994.
130. **Wagner LI**, Banghart MA, Ferrari JR, et al. Health-care systems and individuals with chronic illness: Small steps for community psychologists. *Poster presented at the annual Midwestern meeting of the Society for Community Research and Action, Liberty, OH*; 1994.
131. Jason LA, Taylor SL, **Wagner L**, et al. Estimating chronic fatigue syndrome-related symptoms among nurses: A preliminary report. *Clin Infect Dis*. 1993;18:S84-85 (abstract).
132. Jason LA, Taylor S, **Wagner L**, Johnson S. Epidemiological approaches in estimating prevalence rates for chronic fatigue syndrome. *Poster presented at the 65th annual meeting of the Midwestern Psychological Association, Chicago, IL*; 1993.

133. Jason LA, **Wagner L**, Taylor R, Holden J, Stenzel CL, Slavich S. Chronic fatigue syndrome: In your mind or in your body. *Paper presented at the annual Midwestern meeting of the Society for Community Research and Action*, Sawyer, MI; 1993.

Editorials – Peer Reviewed:

1. **Wagner LI**. Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation. *J Natl Cancer Inst*. 2021;113(8):945-947.
2. Cella D, **Wagner L**. Re-personalizing precision medicine: Is there a role for patient-reported outcomes? *J Community Support Oncol*. 2015;13: 275-277.
3. Evens AM, **Wagner LI**., Curing Hodgkin’s lymphoma: Quantity and quality. *Lancet Oncology*. 2009;10:1134-1135.

Products of Scholarship in Teaching, Clinical Research, and Practice: Invited Lectures

1. *Moving Patient Care Forward: The Impact of Quality-of-Life (QOL) Studies*. Invited lecture, NCORP Annual Meeting. August 2022
2. *Harnessing the Power of NCORP-Collected PRO Data to Optimize Patient Care: Key Findings from the NCI Moonshot Treatment Tolerability Consortium*. Invited lecture, NCORP Annual Meeting. August 2022
3. Moderator, International Cancer and Cognition Task Force webinar, Subjective cognitive decline as a precursor of objective cognitive decline. March 2022.
4. Discussant, Health Services Research and Quality Improvement Oral Abstract Session, American Society of Clinical Oncology (ASCO) 2020 Annual Meeting. Chicago, IL (2020).
5. *Patient reported outcomes in kidney cancer*. Invited lecture, Vision of Hope: A kidney cancer educational symposium. Philadelphia, PA. (2019).
6. *Innovations in Digital Health Technologies: Applications in Cancer*. Invited lecture, Plenary Session, Society of Integrative Oncology Annual Meeting. Chicago, IL (2017).
7. *NCI Community Oncology Research Program: Accomplishments, Challenges, and Opportunities*. Invited lecture, Harry E. Hynes Memorial Lecture, Plenary Session, Southwest Oncology Group (SWOG) Cancer Research Network Annual Meeting, Chicago IL (2015).
8. *eHealth Strategies to Screen for and Treat Distress among Adults with Cancer: Levering NIH-funded Resources*. Invited lecture, Health Outcomes Lecture Series, University of North Carolina. Chapel Hill, NC. (2015).
9. *The Commission on Cancer’s Psychosocial Distress Screening Quality Care Standard: How and why it was adopted*. Plenary Session, American Psychosocial Oncology Society 11th Annual Conference, Tampa FL (2014).
10. *“Meet the experts” in Distress Screening*. American Psychosocial Oncology Society 11th Annual Conference, Tampa, FL (2013).

11. *A New Era for Cancer Care Delivery: Psychosocial Care Standards*. Screening for Psychosocial Distress Program, American Psychosocial Oncology Society, Tampa FL (2013).
12. Training Supportive Care Professionals In Implementing Comprehensive Biopsychosocial Screening (Award R25CA160049; PI: Loscalzo). Webinar recorded in New York, NY (2013).
13. *Distress screening: Accreditation standards and clinical practice guidelines; Implementation and Case Examples*. American College of Surgeons Commission on Cancer, Chicago, IL (2013).
14. *Bringing advances in measurement science to the clinical forefront: Integrating NIH Patient-Reported Outcomes Measurement Information System (PROMIS) tools into routine cancer care*. American Society of Clinical Oncology Quality Care Symposium, San Diego, CA (2013).
15. *"Meet the experts" in Distress Screening*. American Psychosocial Oncology Society 10th Annual Conference, Huntington Beach, CA (2013).
16. *Measuring Quality of Life in Dermatologic Oncology*. First Annual Memorial Sloan Kettering Dermatologic Oncology Conference. New York, NY (2012).
17. *Psychosocial Late Effects among Cancer Survivors*. National Cancer Institute Community Clinical Oncology Program Research Base Investigators meeting. Bethesda, MD (2012).
18. *Cancer Program Standards 2012 Continuum of Care Services: Psychosocial Distress Screening, Tools and Resources [webinar]*. Retrieved December 1, 2011, from <http://www.facs.org/cancer>.
19. *Cognitive dysfunction during and after cancer treatment: Latest research findings and strategies for clinical management*. Sixth Annual Oncology Congress. New York Medical College and Reed Medical Education. San Francisco, CA (2010).
20. *Depression and Depression Screening*. Clinical Research Associate Educational Session. Radiation Therapy Oncology Group meeting. Tampa, FL (2010)
21. *Cancer, cancer treatment, and cognitive function: What do we know about this symptom? What are some ways to cope?* 9th Annual Conference for Young Women Affected by Breast Cancer. Dallas, TX (2009).
22. *Coping with cognitive changes during and after cancer treatment*. ShareRing Network National Teleconference. Breast Cancer Network of Strength (2009).
23. *Cognitive function and symptom assessment in the TAILORx trial*. General Session, Eastern Cooperative Oncology Group (ECOG) Group meeting. Baltimore, MD (2009).
24. *Quality of life in breast cancer: Priority trial ECOG protocol E2Z04*. Scientific Leadership Council in Breast Cancer. Coalition of Cancer Cooperative Groups. Dallas TX (2008).
25. *Cancer, cancer treatment, and cognitive function: Latest research findings and strategies for clinical management*. Chemotherapy Foundation Symposium XXVI. New York City, NY (2008).
26. *Measuring perceived cognitive function. Workshop on Cognitive Dysfunction Associated with Chemotherapy*. International Cancer in Cognition Task Force (ICCTF) Workshop. Amsterdam, Netherlands (2008).
27. *Psychological Impact and Quality of Life Issues Associated with Therapy-Induced Rashes*. Educational Symposium, Oncology Nurses Society. Las Vegas, NV (2007).

28. *Functional Assessment of Cancer Therapy (FACT) questionnaire for the assessment of dermatology-related quality of life in patients treated with EGFR inhibitors.* Global Health Economics and Outcomes Research Seminar, Amgen Inc. Thousand Oaks, CA (2006).
29. *Update on Cognitive Function Research at CORE: Measuring patient reported cognitive impairments.* Workshop on Cognitive Dysfunction Associated with Chemotherapy. International Cognitive Function and Cancer Working Group (Chair: Ian Tannock, M.D.). Venice, Italy (2006).
30. *Phase I and Phase II clinical trials and patient-reported outcomes.* Speaker and Session Chair. Patient-reported outcomes assessment in cancer trials: Evaluating and enhancing the payoff to decision-making. National Cancer Institute. Washington, DC (2006).
31. *Cognitive functioning among patients with cancer.* Global Health Economics and Outcomes Research Seminar, Amgen Inc. Thousand Oaks, CA (2005).
32. *Cognitive Dysfunction Associated with Cancer and Cancer Treatments: Do We Know Enough to Consider Treatments?* MD Anderson Symptom Management Annual Conference. Houston, TX (2005).
33. *Prechemotherapy cognitive function in patients with cancer.* Education Session, Geriatric Oncology. American Society of Clinical Oncology 41st Annual Meeting. Orlando, FL (2005).
34. *Getting Distress Management on the Oncologist's Radar: The Northwestern Experience.* Special Session: Recognizing and Treating Distress in Clinic Patients: Rapid Screening and Impact on Quality of Life of Patients. Moderator: Jimmie Holland, M.D. American Society of Clinical Oncology 40th Annual Meeting, New Orleans, LA (2004).
35. *ECOG Symptom management clinical research initiative.* Eastern Cooperative Oncology Group General Session. Eastern Cooperative Oncology Group (ECOG) Group meeting. New Orleans, LA (2003).
36. *Breast cancer and health-related quality of life.* Eastern Cooperative Oncology Group Breast Committee. Eastern Cooperative Oncology Group (ECOG) Group meeting. New Orleans, LA (2003).
37. *Development of the Functional Assessment of Cancer Therapy – Cognitive Function (FACT-Cog).* Workshop on Cognitive Dysfunction Associated with Chemotherapy. International Cognitive Function and Cancer Working Group (Chair: Ian Tannock, M.D.). Banff, Alberta (2003).
38. *Measuring Quality of Life and Cognitive Function during Breast Cancer Chemotherapy.* Maintaining Function During Adjuvant Breast Cancer Therapy: Quality of Life and Cognition. Second International Breast Cancer Congress. Banff, Alberta (2003).

Published Audio and Video

- Invited Interview**, *Med Page Today* September, 2020
 Cancer-Related Cognitive Impairment in Early Breast Cancer
 Based on my recognized expertise in psychosocial oncology, I was interviewed regarding ECOG-ACRIN TAILORx trial results on patient-reported cognitive function.
- Invited Lecture**, *ECOG-ACRIN Cancer Research Group Town Hall* April, 2020
 “Managing COVID-related distress: Resources for cancer patients and providers”

Based on my expertise in psychosocial oncology and my visibility within the ECOG-ACRIN Cancer Research Group, I presented during a Town Hall meeting to provide our collaborative network of community oncology practices with resources on managing COVID-related distress.

Invited podcast, *Journal of Clinical Oncology*

May, 2017

“Discussion of the SWORD-study and fear of cancer recurrence intervention research”

(<https://ascopubs.org/doi/10.1200/JCO.2016.70.5301>)

Based on my recognized expertise in psychosocial oncology and fear of cancer recurrence research, I was invited to record a podcast to accompany a JCO publication.

Invited Publications (Editorially Reviewed)

1. **Wagner LI.** Introduction to adolescent and young adult series. *Cancer*. 2014;120:2226.
2. Holland JC, Andersen B, **Wagner LI**, et al. Distress management. *Journal of the National Comprehensive Cancer Network*. 2013;11:190-209.
3. Berger AM, Abernethy AP, **Wagner LI**, et al. Cancer-related fatigue. *Journal of the National Comprehensive Cancer Network*. 2010;8:904-931.
4. Holland JC, Andersen B, **Wagner LI**, et al. Distress management: Clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*. 2010;8:448-485.
5. **Wagner LI.** Brief Cognitive Behavioral Therapy to Manage Chemotherapy-Related Cognitive Impairments (“chemo-brain”): A Case Example. *Oncology Nurse Edition*. 2010;24:50-54.
6. **Wagner LI**, Lacouture M. Clinical psychologist’s perspective on dermatologic toxicities associated with EGFR inhibitors: Impact on health-related quality of life and implications for clinical management of psychological sequelae. *Oncologist*. 2007;21:34-36.

TEACHING ACTIVITIES:

Didactic and Systematic Instruction

Invited lecturer

March, 2021

Topic: *Using PRO measurement science to bring the patient’s voice to the clinical encounter and promote a learning health system*

2021 Colloquium, Wake Forest Center for Biomedical Informatics

Virtual attendees: 150

Invited lecturer

September, 2019

Topic: *Patient-reported outcomes and PROMIS integration to improve cancer care delivery*

Cancer Survivorship Program Seminar Series, Wake Forest Baptist Comprehensive Cancer Center

Attendees: 20

Invited lecturer

July, 2018

Topic: *Integration of PROMIS PROs with EMR integration*

Bioinformatics Short Course, Wake Forest University School of Medicine

Number of students: 50

Seminar series coordinator

September 2016 – May 2018

Cancer Survivorship Fellowship (R25) Trainee Seminar Series

Department of Social Sciences and Health Policy, Wake Forest University School of Medicine

Number of post-doctoral trainees: 5

Invited lecturer

January 2017- Present

Course: THSS 742: *Clinical Trials Methods (3.0 credits; Required)*

Master of Science Program in Translational and Health System Science

Division of Public Health Sciences, Wake Forest University School of Medicine

Number of students: 10

Invited lecturer

January 2017- Present

Course: THSS748: *Population Research Methods I (2.0 credits; Required)*

Master of Science Program in Translational and Health System Science

Division of Public Health Sciences, Wake Forest University School of Medicine

Number of students: 12

Invited lecturer

January 2017- Present

Course: THSS749: *Population Research Methods II (3.0 credits; Required)*

Master of Science Program in Translational and Health System Science

Division of Public Health Sciences, Wake Forest University School of Medicine

Number of students: 15

Course Co-Instructor

September-December, 2016

Course: CPTS748: *Conceptual Foundations of Community and Health Services Research (2.0 credits; Required)*

Master of Science Program in Clinical and Population Translational Science Department

Division of Public Health Sciences, Wake Forest School of Medicine

Number of students: 16

Course Instructor

January-April 1996

Course: PSY302: *Personal Adjustment and Mental Health (3.0 credits; Elective)*

Department of Psychology, DePaul University

Number of students: 30

Course Instructor

September-December 1995

Course: PSY105: *Introduction to Psychology (4.0 credits; Elective)*

Department of Psychology, DePaul University

Number of students: 45

Mentorship:Undergraduate Students

1. Fuyuan Zheng 2021-2022
Mentor, Health Policy and Administration internship
Wake Forest University
Current Position: Student, Columbia University, Masters in Fine Arts program
2. Lauren Zaluda 2010-2011
Mentor, Volunteer research internship
Current position: Instructor of Psychology, Rush University Medical Center

Graduate Students

3. Kile King 2011-2012
Thesis advisor, Master of Science in Clinical Research and Regulatory Administration
Current position: Assistant Director of Research Administration and Compliance, Harvard Business School

Postdoctoral Fellows

4. Alayna Ernster, Ph.D. 2022-Present
Secondary mentor, Postdoctoral research fellow (T32)
Wake Forest University School of Medicine
5. Sarah Price, Ph.D. 2022-Present
Secondary mentor, Postdoctoral research fellow (T32)
Wake Forest University School of Medicine
6. Brianna Leitzelar, Ph.D. 2021-Present
Secondary mentor, Postdoctoral research fellow (T32)
Wake Forest University School of Medicine
7. Neha Goyal, Ph.D. 2017-2019
Secondary mentor, Postdoctoral research fellow
Current position: Staff psychologist, Weill Institute for Neurosciences, University of California, San Francisco
8. Laurie Steffen McLouth, Ph.D. 2017-2019
Secondary mentor, Postdoctoral research fellow
Current position: Assistant Professor, Department of Behavioral Science Markey Cancer Center, Center for Health Equity Transformation, University of Kentucky College of Medicine
9. Alexander Lucas, Ph.D. 2016-2018
Secondary mentor, Postdoctoral research fellow
Current position: Instructor, Department of Health Behavior and Policy & Department of Internal Medicine, Virginia Commonwealth University, School of Medicine
10. Zeeshan Butt, Ph.D. 2004-2006
Primary mentor, Postdoctoral research fellow

Current position: Associate Professor, Department of Medical Social Sciences, Northwestern University
Feinberg School of Medicine

Clinical Trainees

11. Director, Supportive Oncology 2006-2011
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Supervised two post-doctoral clinical trainees and two early career faculty members in obtaining clinical hours toward licensure

Faculty

12. Dori Beeler, Ph.D., Adjunct Assistant Professor 2022 – present
Department of Internal Medicine, Hematology and Oncology, Wake Forest School of Medicine
Member, Mentoring Committee
13. Daniel Hall, Ph.D., Assistant Professor 2019 – present
Harvard Medical School; Faculty, Health Promotion and Resiliency Intervention Research Program and Health Policy Research Center, Mongan Institute; Staff Psychologist, Behavioral Medicine Program and Center for Psychiatric Oncology & Behavioral Sciences; Massachusetts General Hospital
Member, Mentoring Committee, Mentored Research Scientist Development Award (K23)
14. Nathaniel O'Connell, Ph.D., Assistant Professor 2019 – present
Department of Biostatistics and Data Science, Wake Forest School of Medicine
Member, Mentoring Committee
15. Joseph Rigdon, Ph.D., Assistant Professor, 2019 – present
Department of Biostatistics and Data Science, Wake Forest School of Medicine
Member, Mentoring Committee
16. Stephanie Sohl, Ph.D., Assistant Professor 2017 – present
NCCIH-funded investigator
Primary mentor, Mentored Research Scientist Development Award (K01)
17. John M. Salsman, Ph.D., Associate Professor 2015 – 2017
NCI-funded investigator
Primary mentor, Career Development Award (K07)

GRANTS

Active Grants

P30 CA012197 (**Wagner, Co-Director**, PI: Blackstock, 5%) February 2022-January 2025
Sponsor: National Cancer Institute \$1,500,000/year direct cost
Title: *Comprehensive Cancer Center of WFU Cancer Center Support Grant (Q-PRO Shared Resource)*
Objectives: The Comprehensive Cancer Center of Wake Forest University is a multidisciplinary interdepartmental research center, organized into four programs: Two Basic Science Programs, Clinical Research, and Cancer Prevention and Control.

- U01 CA243702 (**Wagner, Co-I**; PI: A Bradbury, 5%) September 2020-August 2025
 Sponsor: National Cancer Institute \$510,318 /year 1 direct cost
 Title: *A Randomized Hybrid Type 1 effectiveness-implementation study of an Ehealth delivery alternative for Cancer genetic testing for Hereditary cancer predisposition (eREACH)*
 Objectives: The aim of this trial is to conduct a Hybrid Type 1 effectiveness-implementation study to evaluate web-based eHealth delivery alternatives for genetic education to evaluate uptake of genetic testing among a nationally diverse sample of patients who face access barriers to counseling and testing, using the Consolidated Framework for Implementation Research to inform future implementation and sustainability.
- 2UG1CA189828 (**Wagner, Contact PI**, M-PI: Schnall, O'Dwyer; 5%) August 2020-July 2025
 Supplement (PI: R. Carlos) \$118,727/year 1 direct cost
 Sponsor: National Cancer Institute
 Title: *COVID-19 RElated Barriers to Trial Participation Equity (CO-RELaTE)*
 Objectives: The aim of this project is to reduce cancer health disparities in women of color (WOC) through increased participation in clinical trials. This trial will assess COVID-related financial hardship among WOC compared to non-WOC and association with trial participation.
- 2UG1CA189828 (**Wagner, Contact PI**, M-PI: Schnall, O'Dwyer; 5%) August 2020-July 2023
 Supplement (PI: J. Salsman) \$61,225/year 1 direct cost
 Sponsor: National Cancer Institute
 Title: *Improving adolescent and young adult self-reported data in ECOG-ACRIN NCORP Trials*
 Objectives: The aim of this project is to conduct a pilot randomized trial with AYAs to determine the feasibility and acceptability of completing PROs informed by AYA priorities vs fixed assessment to improve upon longitudinal PRO data capture
- 1R21CA226960 (**Wagner, Co-I**, PI, G. Hundley, 3%) February 2019-January 2024
 Sponsor: National Cancer Institute \$193,301/year direct cost
 Title: *Does a tailored-progressive physical activity intervention before and during non-Hodgkin lymphoma anthracycline-based chemotherapy preserve exercise capacity, QOL, cardiac and cognitive function?*
 Objectives: The purpose of this project is to conduct a pilot study to evaluate and refine a physical activity intervention for adults with non-Hodgkin lymphoma followed by a randomized trial to evaluate the effects of a physical activity intervention on exercise capacity, quality of life, cardiac and cognitive function.
- 1R01CA242849 (**Wagner, Co-I**, PIs: J. Salsman, J.T. Moskowitz, 5%) July 2019 – June 2023
 Sponsor: National Cancer Institute \$368,264/year direct cost
 Title: *Using MOST to EMPOWER: Optimizing an emotion Regulation intervention to enhance well-being among young adult cancer survivor*
 Objectives: The main objective of this study is to optimize a multi-component intervention for young adult cancer survivors (EMPOWER) by using an innovative methodological framework, the Multiphase Optimization Strategy (MOST), to determine which intervention components are effective in reducing distress and promoting well-being.

1U01CA233169 (**M-PI, Wagner**, R. Gray, 15%) September 2018-August 2023
 Sponsor: National Cancer Institute \$533,799 /year 4 direct cost
 Title: *Analysis of ECOG-ACRIN Adverse Event Data to Optimize Strategies for the Longitudinal Assessment of Tolerability in the Context of Evolving Cancer Treatment Paradigms (EVOLV)*
 Objectives: The aim of this project is to evaluate ECOG-ACRIN Adverse Event Data collected from clinical participants to improve our understanding of the tolerability of cancer treatment.

R01 CA214427-01A1 (**Wagner, Co-I**, M-PI: E. Park, J. Ostroff, 8%) February 2018-July 2023
 Sponsor: National Cancer Institute \$486,098/year direct cost
 Title: *Implementing a Virtual Tobacco Treatment in Community Oncology Practices*
 Objectives: The objective of this project is to disseminate and evaluate a patient-centered, evidence-based mHealth tobacco treatment for newly diagnosed cancer patients through in collaboration with community-based oncology settings through the ECOG-ACRIN NCORP Research Base.

2UG1CA189828 (**Wagner, Contact PI**, M-PI: Schnall, O'Dwyer; 50%) August 2014-July 2025
 Sponsor: National Cancer Institute \$23,799,135/year 6 direct cost
 Title: *ECOG-ACRIN NCI Community Oncology Research Program (NCORP) Research Base*
 Objectives: This NCORP Research Base grant supports the ECOG-ACRIN Cancer Research Group Cancer Control and Outcomes Program.

Completed Grants (Direct costs)

Wagner, Co-Director (\$30,000), July 2019-June 2021
 Sponsor: National Institutes of Health (UL1)
 Title: *Wake Forest Clinical and Translational Science Award, Qualitative and Patient-Reported Outcomes Shared Resource*

Wagner, PI , (\$25,000) December 2016-November 2017
 Sponsor: Carolina Collaboratives Grant (CTSA)
 Title: *Harmonization of patient-reported outcomes across 4 CTSA: Leveraging EHRs to enable comparative effectiveness research to improve the quality of cancer care*

Wagner, Co-PI, Co-PI: M. Canzona, (\$25,000) August 2016-July 2017
 Sponsor: Maya Angelou Center for Health Equity, Cross-campus pilot award
 Title: *Mixed methods study to understand diverse cancer patients' experiences with precision oncology*

Wagner, Schnall, Co-PIs, (\$49,148,095) September 2014-August 2019
 Sponsor: National Cancer Institute
 Title: *ECOG-ACRIN NCI Community Oncology Research Program (NCORP) Research Base*

Wagner, Program Faculty, PI, Avis, 5%, (\$445,271) August 2014-July 2019
 Sponsor: National Cancer Institute (R25)
 Title: *Postdoctoral Training Program in Cancer Survivorship*

- Wagner, Co-I**; Institutional PI, PI: F. Albinali, (\$201,683) January 2014-June 2016
Sponsor: National Cancer Institute (SBIR grant)
Title: *COMPASS: Capturing and Analyzing Sensor and Self-report Data for Clinicians and Researchers*
- Wagner, PI**, (\$39,000) March 2013-February 2015
Sponsor: Gollub Foundation
Title: *Implementing psychosocial, lifestyle, and symptom screening in routine breast cancer care to improve delivery of patient-centered care*
- Wagner, PI**, (\$271,636) February 2013-January 2016
Sponsor: National Cancer Institute (R21)
Title: *Targeted eHealth intervention to reduce fear of cancer recurrence among breast cancer survivors*
- Wagner, Co-I**, PI: Wang, (\$329,939) September 2012-June 2017
Sponsor: National Institute of Nursing Research (R01)
Title: *PCI Hippocampal Predictors of Cognitive Impairment in Breast Cancer Patients*
- Wagner, Co-I**, PI: S. Rosen, (\$76,024) August 2012-July 2017
Sponsor: National Cancer Institute/National Institutes of Health
Title: *The Robert H. Lurie Comprehensive Cancer Center of Northwestern University Outcomes Measurement and Survey Core*
- Wagner, Co-I**, PI: Voss, (\$50,000) 2012-2014
Sponsor: Lynn Sage Foundation
Title: *Pinpointing the Neuropathology of Cognitive Impairment in Breast Cancer*
- Wagner, Co-I**, Institutional PI, (\$5,872-subcontract amount) January 2012-May 2012
Sponsor: National Cancer Institute
Title: *ECOG and ACRIN Consolidation*
- Wagner, Co-I**, Protocol Study Chair, PI: W. Curran, (\$38,392) September 2009-August 2011
Sponsor: Pennsylvania Department of Health, Commonwealth Universal Research Enhancement
Title: *Radiation Therapy Oncology Group (RTOG 0841) Efficiency of Screening for Depression in Cancer Patients Receiving Radiotherapy*
- Wagner, Co-I**, PI: J. Lai, (\$1,141,337) August 2009-July 2011
Sponsor: National Cancer Institute/The National Institute of Health
Title: *Perceived cognitive function item bank for children who undergo cancer treatment*
- Wagner, Co-I**, Institutional PI, PI: Comis, (\$394,585-sub-contract amount) June 2009-July 2014
Sponsor: National Cancer Institute
Title: *ECOG-ACRIN Cancer Control and Outcomes Research Program*

- Wagner, Co-I**, PI: L. Emanuel, (\$250,425) September 2007-June 2012
Sponsor: National Institute of Child Health and Human Development/National Institutes of Health (from 10/1/09-03/31/11 only)
Title: *R01D: An Interdisciplinary Perspective: A Social Science Examination of Oncofertility*
- Wagner, Co-I**, PI: D. Mohr, (\$591,978) September 2007-June 2010
Sponsor: National Institute of Child Health and Human Development/National Institutes of Health
Title: *A controlled trial of CBT for MS inflammation*
- Wagner, Co-I**, PI: S. Yount, (\$973,267) September 2005-June 2009
Sponsor: National Cancer Institute/National Institutes of Health
Title: *Weekly symptom telemanagement in advanced lung cancer*
- Wagner, Co-I**, PI: D. Cella, (\$76,000) April 2005-February 2011
Sponsor: National Cancer Institute
Title: *Item banking and computer adaptive testing for quality of life outcomes*
- Wagner, Co-I**, PI: D. Cella, (\$1,229,789) September 2004-April 2011
Sponsor: National Institutes of Health
Title: *NIH PROMIS Statistical Coordinating Center*
- Wagner, Co-I**, PI: D. Cella, (\$76,024) September 2004-April 2011
Sponsor: National Cancer Institute/National Institutes of Health
Title: *Administrative Supplement to NIH PROMIS Statistical Coordinating Center*
- Wagner, Co-I**, Primary Mentor, PI: D. Cella, (\$125,000) June 2004-May 2006
Sponsor: OrthoBiotech LLC
Title: *Post-doctoral fellowship in fatigue*
- Wagner, Co-I**, PI: V. Champion, (\$304,587) January 2004-December 2010
Sponsor: American Cancer Society
Title: *Quality of life in younger breast cancer survivors*
- Wagner, Co-I**, PI: S. Rosen, (\$165,925) August 2003-July 2012
Sponsor: National Cancer Institute/National Institutes of Health
Title: *The Robert H. Lurie Comprehensive Cancer Center of Northwestern University Outcomes Measurement and Survey Core*
- Wagner, PI**, (\$245,200) September 2001-August 2004
Sponsor: OrthoBiotech LLC
Title: *Objective and subjective neurocognitive problems associated with chemotherapy for breast cancer*
- Wagner, Co-I**, Project Coordinator, PI: D. Cella, (\$250,000) July 2001-June 2003
Sponsor: OrthoBiotech LLC

Title: *Cancer symptom management clinical research program*

Wagner, Co-I, PI: Comis, (\$60,000)

June 2001-May 2012

Sponsor: National Cancer Institute/The National Institutes of Health

Title: *Eastern Cooperative Oncology Group Patient Outcomes and Survivorship Committee*

PROFESSIONAL SERVICE

Institutional Quality Improvement Initiatives

Collaborator 2019-Present

Integration of PROMIS measures in cancer survivorship care

Implementation: Wake Forest Baptist Comprehensive Cancer Center Survivorship Clinic

Collaborated with Dr. Stacy Wentworth, Medical Director, Cancer Survivorship Clinic to advise on implementation of PROMIS patient-reported outcomes measures to assess distress and key symptoms among outpatients attending the newly established cancer survivorship clinic based on model established at prior institution. Collaborating on similar initiatives in Surgical Oncology (P. Shen), Radiation Oncology (R. Hughes), and Precision Oncology (S. Grant, B. Pasche).

Project Leader, 2011-2015

Bringing PROMIS to practice: Implementing PROMIS patient-reported outcomes in cancer care delivery with electronic health record integration

Implementation: National, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Led an initiative to implement innovative patient-reported outcomes, PROMIS computer adaptive tests, with electronic health record integration to facilitate clinical assessment and triage. This initiative advanced a model that has been adopted by cancer centers nationally and set the platform for data extraction and evaluation, presented in several publications.

Comprehensive Cancer Center Service

Co-Leader, 2017-Present

Cancer Control and Survivorship Disease Oriented Team

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Co-Director, 2016-2023

Qualitative and Patient-Reported Outcomes Research (Q-PRO) Shared Resource

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Director of Research and Clinical Integration, 2015-Present

Cancer Prevention and Control Program

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Director of Translational Research, Cancer Survivorship Institute 2012-2015

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Director, Supportive Oncology 2006-2011
 Robert H. Lurie Comprehensive Cancer Center of Northwestern University at the Northwestern Medical Faculty Foundation

Institutional Service

Member, Faculty Search Committee 2018-2020
 Position: Associate Chief, Learning Health System Research General Internal Medicine
 Wake Forest Baptist Health, Wake Forest School of Medicine

Member, National Clinical Trials Network Oversight Committee 2014-2015
 Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Member, STAR (Survivors Taking Action and Responsibility) Program Advisory Board 2009-2015
 Northwestern Medical Faculty Foundation

Member, Committee on Cancer 2008-2015
 Northwestern Memorial Hospital

Member, Community Outreach Committee 2003-2008
 Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Member and Reviewer, 2002-2015
 Clinical Protocol and Scientific Review Monitoring System Committee
 Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Steering Committee Member, 2002-2006
 Women's Faculty Organization Northwestern University

Panel Member, 2000-2006
 Office for the Protection of Research Subjects, Northwestern University

Departmental Service

Member, Division of Public Health Sciences Education Committee 2018-present
 Representative for the Department of Social Sciences and Health Policy,
 Division of Public Health Sciences, Wake Forest School of Medicine

Chair, Planning Committee, Division of Public Health Sciences Faculty Retreat 2018-2019
 Representative for the Department of Social Sciences and Health Policy,
 Division of Public Health Sciences, Wake Forest School of Medicine

Member, Promotions Review Committee 2017-present
 Research Assistant, Research Associate and Senior Research Associate Track
 Department of Social Sciences and Health Policy,
 Division of Public Health Sciences, Wake Forest School of Medicine

Member, Faculty Search Committees 2010-2015
Department of Medical Social Sciences Northwestern University Feinberg Medical School

Chair, Faculty Search Committee 2010-2011
Department of Medical Social Sciences Northwestern University Feinberg Medical School

Member, Appointment, Promotion and Tenure Committee 2009-2015
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine

Funding Agency Reviewer

Review panel Co-Chair 2023
 NCI: Special Emphasis Panel Research to understand and address the survivorship needs of individuals living with advanced cancer

Scientific grant reviewer 2022-2023
 Florida Breast Cancer Foundation

Canadian Cancer Trials Group Review Panel 2021
 Canadian Cancer Society,

UM1, U24; Reviewer 2018
 NCI: Moonshot Initiative Special Emphasis Panel on Cancer Symptom Management

R21, R01; Ad-hoc reviewer, 2017
 NIH: Methodology and Measurement in the Behavioral Social Sciences

R01; Reviewer 2016
 NCI: Special Emphasis Panel

Reviewer 2016-Present
 NCI: Special Emphasis Panel, Program Project Grants

Ad-hoc Reviewer 2012-Present
 NCI: Subcommittee F

Ad-hoc Reviewer 2009-2011
 NCI: Subcommittee G, Clinical Community Oncology Program Research Base Program

Scientific Reviewer 2006-2008
 Lance Armstrong Foundation Research Programs

Editorial Board Member

Section Editor, *Cancer, Symptom Management and Palliative Care* 2011-2021

Journal Reviewer

Ad-hoc Reviewer,	<i>Journal of the National Cancer Institute</i>	2021-Present
Ad-hoc Reviewer,	<i>Journal of Cancer Survivorship</i>	2012-Present
Ad-hoc Reviewer,	<i>AIDS and Behavior</i>	1997-1999
Ad-hoc Reviewer,	<i>Leukemia and Lymphoma</i>	2010-Present
Ad-hoc Reviewer,	<i>Journal of Supportive Care in Cancer</i>	2010-Present
Ad-hoc Reviewer,	<i>Clinical Breast Cancer Review</i>	2009-Present
Ad-hoc Reviewer,	<i>Cancer</i>	2008-Present
Ad-hoc Reviewer,	<i>Journal of Clinical Oncology</i>	2007-Present
Ad-hoc Reviewer,	<i>Journal of Pain and Symptom Management</i>	2006-Present
Ad-hoc Reviewer,	<i>Quality of Life Research</i>	2005-Present
Ad-hoc Reviewer,	<i>American Journal of Cancer</i>	2002-Present
Ad-hoc Reviewer,	<i>Clinical Cancer Research</i>	2002-Present
Ad-hoc Reviewer,	<i>Psycho-Oncology</i>	2001-Present
Ad-hoc Reviewer,	<i>Quality of Life Research</i>	2000-Present

Conference Planning

Member (Committee Chair, 2011-2012) American Society of Clinical Oncology (ASCO) ASCO Annual Meeting Scientific Planning Committee, Health Services Research Track	2011-2015
---	-----------

Advisory Board Member

Expert Panel member , Integrative Approach to Pain Management Joint Society of Integrative Oncology-American Society of Clinical Oncology Clinical Practice Guidelines panel	2020-Present
Member , Scientific Steering Committee, Connect Multiple Myeloma Registry Celgene Corporation/Bristol Myers Squibb	2016 – Present
Member , Standard of Care Committee Alliance for Quality Psychosocial Cancer Care	2009-2015
Member Representative on behalf of the American Psychosocial Oncology Society, American College of Surgeons Commission on Cancer	2009-2015
Expert Panel Member National Comprehensive Cancer Network Distress Management Panel	2008-2015

Expert Panel Member 2002-2015
National Comprehensive Cancer Network Cancer-Related Fatigue Panel

NCI Funded Clinical Trials Network (NCTN and NCORP) Advisory Board and Steering Committee Member
Member, 2020-Present
Symptom Management and Quality of Life Steering Committee Clinical Trial
Planning Meeting Working Group, Cancer-Related Cognitive Impairment, *National Cancer Institute*

Co-Leader, 2013-2015
Patient Reported Outcomes/Health-Related Quality of Life Working Group,
National Cancer Institute

Committee Member, 2013-2014
Clinical Trials Planning Meeting, *NCI Lymphoma Steering Committee*

Steering Committee Member, 2010-Present
Lymphoma Steering Committee, *National Cancer Institute*

Member, 2010
Research Priorities Committee, Clinical Community Oncology Program Strategic
Planning Committee, *National Cancer Institute*

Steering Committee Member, 2007-Present
Symptom Management and Quality of Life Intergroup Steering Committee,
National Cancer Institute

Session Chair, 2006
Patient-Reported Outcomes and Phase II Cancer Treatment Trials: Value
Added and Lessons Learned, *NCI State-of-the-Science Conference, PROs and Cancer Clinical Trials*

NCI Funded Clinical Trials Network Service Activities (NCTN and NCORP)
Member, ECOG-ACRIN Task Force on the Advancement of Women 2021-Present

Member, 2020-Present
NCTN Adolescent and Young Adult (AYA) Patient-Reported Outcomes Task Force (Chairs: Michael Roth,
Susan Parsons)

Committee Chair, Cancer Control and Survivorship Committee 2014-Present
ECOG-ACRIN Cancer Research Group

Deputy Chair, 2013-Present
ECOG-ACRIN Cancer Research Group Cancer Control and Outcomes Program
ECOG-ACRIN Executive Committee,
ECOG-ACRIN Executive Review Committee,

ECOG-ACRIN Scientific Planning Committee

Co-Chair, Breast Cancer Survivorship Working Group, Breast Committee 2010-2017
ECOG-ACRIN Cancer Research Group

Committee Chair, Patient-Centered Outcomes and Survivorship Committee 2009-2014
ECOG-ACRIN Cancer Research Group

Study Chair, 2009-2020
 RTOG 0841: Efficiency of screening for depression in cancer patients receiving radiotherapy
Radiation Therapy Oncology Group

Member, *Gynecologic Oncology Group* 2007-2014

Committee Co-Chair, Patient Outcomes and Survivorship Committee 2005-2009
ECOG-ACRIN Cancer Research Group

Study Chair, 2003-2013
 ECOG E1203: Quality of life companion study for JMA.27 (NCIC-MA.27): A randomized Phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer
ECOG-ACRIN Cancer Research Group

Committee Co-Chair, Symptom Management Consortium 2003-2009
ECOG-ACRIN Cancer Research Group

Patient-Reported Outcomes Measurement and Quality of Life Study Co-Chair, 2001-Present
ECOG-ACRIN Cancer Research Group

Disease and Modality Committee protocols in various disease areas (breast, gastrointestinal, leukemia, lung, lymphoma, myeloma, neuro-oncology, screening and surveillance, symptom science)

Member, *ECOG-ACRIN Cancer Research Group* 2001-Present
 (formerly *Eastern Cooperative Oncology Group*)

Public Outreach

Expert interview, 2022
 Childhood Cancer Data Initiative Newsletter
 I was invited for an interview for the CCDI newsletter as a recognized member of the childhood cancer research community.

Expert interview, 2020
 News outlets: *Cancer Discovery, ASCO Daily News, ASCO Post, HemOnc Today, Medscape*
 I participated in several recent interviews on the topic of cancer-related cognitive impairment, related to my April 2020 publication in the *Journal of Clinical Oncology*.

Expert interview, 2020

News outlet: *Insider*

I participated in an interview regarding a celebrity's recent disclosure of a stage IV breast cancer recurrence while she continued to film a popular show. I commented on the psychological aspects associated with cancer recurrence and maintaining employment.

Expert interview, 2020

News outlet: *British Broadcasting Corporation (BBC)*

I was interviewed for a BBC program on "Fighting talk: How language can make us better" as an expert in psychosocial oncology, to address the emotional aspects of cancer survivorship and the importance of the language we use.

Community Activities and Service

Volunteer, Expert Consultant; 2016-Present

Mattie Miracle Cancer Foundation

The Mattie Miracle Cancer Foundation is a non-profit organization dedicated to addressing the psychological, social, and emotional needs of children with cancer and their families. I have provided volunteer services in advising on how to promote the implementation of distress screening in pediatric oncology settings. My work has led to me presenting to members of the Congress, policy makers, and cancer patient advocates in Washington, D.C.

Member, Medical Advisory Board; 2010-Present

Imerman Angels

Imerman Angels is a non-profit organization that provides peer-to-peer matching for adults newly diagnosed with cancer. As a member of the Medical Advisory Board, I provide consultation on the peer matching process, how to manage cancer survivors who report acute distress or present psychosocial-related challenges, and processes for screening peer mentors. I have also provided consultation on how to evaluate outcomes.

PRACTICE

Clinical Health Psychologist 2005-2015

*Northwestern Medical Faculty Foundation and Northwestern Memorial Hospital,
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois*

As a Clinical Psychologist at the Lurie Cancer Center, I assessed and treated patients in collaboration with two inter-disciplinary teams through two clinics: (1) Survivors Taking Action and Responsibility (STAR) Program for adult survivors of pediatric malignancies, and (2) the Cutaneous Lymphoma Clinic. Through the STAR program, I assessed patients who attended clinic annually for risk-based care. I assessed patients for mood and anxiety disorders, and assessed health behaviors. When indicated, I provided individual treatment for STAR program patients to address psychosocial needs. During my time as a provider with the STAR Program, I incorporated clinical training for clinical psychology interns and post-doctoral fellows. Given the variety of concerns patients presented with, the STAR Program provided an ideal platform for

clinical psychology trainee experience and supervision. In the Cutaneous Lymphoma Clinic, I routinely assessed adults with cutaneous lymphoma for mood and anxiety disorders. I provided brief, cognitive behavioral therapy-based intervention for the management of cancer-related symptoms (eg. pruritus, sleep disturbance) and anxiety about disease and symptom progression.

I also maintained a weekly, outpatient clinic through which I assessed and treated adults with various cancer types, including adults newly diagnosed with cancer, with metastatic cancer, and cancer survivors post-treatment. My clinical practice focused on utilizing cognitive behavioral therapy-based strategies to teach patients coping skills for managing adjustment to cancer, symptom management, and mood and anxiety disorders. Through my clinical practice, I tailored cognitive behavioral therapy techniques for the management of anxiety about recurrence. After developing a clinical protocol for treating fear of recurrence, I obtained extramural funding (1R21CA173193-01A1), translated my clinical practice into an eHealth format for asynchronous delivery, and evaluated the eHealth intervention (“FoRtitude”) to reduce fear of recurrence using a Multiphase Optimization Strategy-based design.